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Summary 
 1 
Summary 
Pur-α (purine-rich element binding protein A) is a multifunctional protein binding to 
ss/dsDNA and RNA. It is involved in replication, transcription, mRNA transport and 
translation in neurons. Homozygous Pur-α mutant mice die within 4 weeks after birth, 
suffering from severe neurological defects. Pur-α unwinds dsDNA in an ATP-independent 
manner, thereby providing access for replication and transcriptional regulators. Still, Pur-α’s 
role in cellular functions is not well understood. 
Pur-α has also been implicated in the pathomechanism of heritable, neurodegenerative 
diseases like ALS/FTLD (amyotrophic lateral sclerosis / frontotemporal lobar degeneration) 
and FXTAS (fragile X-associated tremor/ataxia syndrome). FXTAS is caused by premutation 
expansions (55-200 CGG repeats) in the 5'UTR of the fmr1 gene. ALS/FTLD can be triggered 
by hexanucleotide (G4C2) repeat expansions in the first intron of the C9orf72 gene. The 
pathological hallmark for both diseases is the formation of neuronal, intranuclear and 
cytoplasmic inclusions. It is thought that these repeat-RNA containing inclusions sequester 
RNA-binding proteins, leading to altered transcription, RNA processing and trafficking. Pur-α 
binds to both types of RNA repeats and accumulates in these pathogenic inclusions. 
The first goal of this study was to gain insights into the molecular principles of Pur-α’s 
binding to nucleic acids and its cellular functions. For this, structural analysis were combined 
with various biochemical in vitro and cellular studies. Here, I present the crystal structure of 
Pur-α/ssDNA co-complex from Drosophila melanogaster at 2.0 Å resolution. The structure 
explains Pur-α’s dsDNA-binding and –unwinding, and its ssDNA stabilizing activity. The 
protein disrupts the base stacking of DNA by intercalation of a highly conserved 
phenylalanine. The importance of this structural feature was confirmed by in vitro unwinding 
assays. NMR titration experiments and EMSAs suggest that short RNA and DNA oligomers 
interact with Pur-α in identical ways. Filter-binding assays confirmed that the main nucleic 
acid binding domain of Pur-α binds two molecules of nucleic acid, as suggested by the crystal 
structure. 
The second aim of this study was to investigate Pur-α’s role in neurodegenerative diseases. 
For this, I generated inducible, mammalian expression vectors coding for the fmr1 5’UTR 
with normal and disease-related CGG-repeats. These vectors have been tested in COS7 and 
HeLa cells and can now be used for establishment of a stable cellular FXTAS model. 
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1. Introduction 
1.1. Purine-rich element binding protein family 
Pur (purine-rich element binding) proteins are nucleic acid-binding proteins that can be found 
from bacteria to mammals (Johnson, 2003). They bind to purine-rich elements conserved in 
origins of replication and gene flanking regions. The Pur family consists of 4 members, 
encoded by genes at three different loci (Bergemann and Johnson, 1992). These four members 
are Pur-α at chromosome 5q31, Pur-β at 7p13 and two isoforms of Pur-γ at 8p11 (Lezon-
Geyda et al., 2001; Liu and Johnson, 2002; Ma et al., 1995). Different transcription 
termination sites generate the two isoforms of Pur-γ: Pur-γ A and B (Liu and Johnson, 2002). 
Except for Pur-γ B, all Pur proteins are expressed as a single, intronless coding sequence (Liu 
and Johnson, 2002). Transcription of Pur-γ B runs through the Pur-γ A termination signal, 
resulting in a very long transcript of which a 30 kb intron becomes spliced out. This splicing 
event results in a loss of the stop codon and a different C-terminus for the protein isoform B 
(Liu and Johnson, 2002). 
Human Pur-α, Pur-β and Pur-γ (both isoforms) possess an N-terminal glycine-rich domain 
and, except for Pur-γ, a C-terminal gluatmine/glutamate-rich region. A so-called “Psycho” 
motif at the C-terminus describing the consensus motif of proline, serine, tyrosine and 
cysteine can be found in all Pur proteins, except for the isoform B of for Pur-γ. 
All vertebrate Pur proteins contain three strongly conserved repeats of approximately 80 
amino acids and are expressed at different time points during development (Graebsch et al., 
2009). While Pur-γ is highly expressed at early stages of mouse embryo development 
(embryonic age 14), Pur-α expression is nearly undetectable at these early stages. Later Pur-γ 
protein levels decrease drastically whereas Pur-α expression reaches a peak at 18-25 days 
after birth, together with Pur-β. These observations implied that Pur-γ is an important factor 
for embryonic or fetal development that becomes replaced by Pur-α and Pur-β at a later 
developmental stage (Itoh et al., 1998; Johnson et al., 2006). 
Pur-α plays multiple roles in cellular regulation including replication, transcription, mRNA 
transport and translation. Pur-α’s various functions are further described in section 1.1.2. 
Pur-β has been implicated in transcriptional repression of genes encoding for muscle-specific 
isoforms of actin and myosin in heart, skeletal muscle and vascular smooth muscle (Knapp et 
al., 2007; Rumora et al., 2013; Zhang et al., 2008). Both Pur-α and Pur-β have been shown to 
be present in the same mRNPs (messenger ribonucleoprotein particle) that is transported in 
dendrites along microtubules by a kinesin motor (Kanai et al., 2004). Interaction of Pur-α and 
Pur-β with nucleic acids results in the formation of multimeric complexes (reviewed by 
Introduction 
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Johnson, 2003; Kim et al., 2008). Still, direct interaction between Pur-α and Pur-β has not 
been shown so far. 
Abberations in all three Pur genes have been implicated in multiple tumor types and cell 
proliferation disorders, including myelodysplastic syndrome, myelogenous leukemia and 
5q31.3 microdeletion syndrome (Pur-α), brain tumors and glioblastoma (Pur-β), 
myeloproliferative syndrome (Pur-γ) (Brizard et al., 1988; Jackson et al., 2010; Lalani et al., 
2014; Lopez-Gines et al., 2006). 
 
 
1.2. Pur-α protein 
Pur-α is the best-studied protein amongst the Pur family members. It was originally purified 
from mouse brain and identified as a ubiquitously expressed nucleic acid-binding protein 
(Haas et al., 1993; Haas et al., 1995). Human Pur-α consists of 322, Drosophila melanogaster 
Pur-α of 274 and mouse Pur-α of 321 amino acids. Whereas mouse Pur-α only differs from 
the human homolog by two amino acids, the Drosophila homolog shares 52% protein 
sequence identity with it. The Pur repeats in Drosophila Pur-α locate to residues 40-107 
(repeat I), 117-185 (repeat II) and 193-256 (repeat III) (Graebsch et al., 2010). 
Graebsch et al. solved the x-ray structure of residues 40-185 from Drosophila Pur-α, which 
constitutes the major part of the DNA/RNA-binding region. This region contains two almost 
identical Pur-repeats, so-called Pur repeat I and II (Pur-α I-II) (Graebsch et al., 2009). They 
interact with each other and form a nucleic acid binding PUR domain (Figure 1.1 A). Each 
repeat consists of a four-stranded anti-parallel β-sheet followed by a C-terminal α-helix. The 
two Pur-repeats are intertwined and thereby form a hydrophobic buried surface, which 
stabilizes the interaction between the two repeats (Figure 1.1 A). This so-called PUR domain, 
consisting of two Pur-repeats, is homologous to the Whirly class of nucleic acid binding folds 
and shows significant structural similarities to the mitochondrial RNA-binding protein-1 and 
2 (MRP-2, MRP-2) as well as to the plant transcription regulator PBF-2 (P24) (Graebsch et al., 
2009). Surface charge analysis revealed negative charges at the α-helices, whereas the β-
sheets contain numerous positively charged residues. These findings implied that the β-sheets 
mediate DNA/RNA-binding whereas the amphiphatic helices might rather contribute to 
protein-protein interactions. Further evidence for nucleic acid binding to the β-sheets was 
given by electrophoretic mobility shift experiments (EMSA) with mutations in the fourth β-
strand in both Pur-repeats, which resulted in reduction of nucleic acid binding (Graebsch et al., 
2009).  
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Analysis of the oligomeric state of Drosophila Pur-α revealed that Pur-α I-II is monomeric in 
solution, whereas Pur-α comprising all three Pur-repeats forms a dimer (Figure 1.1 B) 
arranging in an unusual Z-like shape (Figure 1.1 C) (Graebsch et al., 2009). This dimerization 
is most likely mediated by the intermolecular interaction of two Pur III repeats (Graebsch et 
al., 2009). 
 
 
Figure 1.1 D. melanogaster Pur-α protein. A: Crystal structure of Pur-α I-II, showing the Whirly-like fold (ββββα) and the intercalation of 
the two repeats. Repeat I and II are depicted in green and blue, respectively. B: Schematic representation of two Pur-α molecules forming a 
dimer. Pur-repeat I and II constitute the DNA/RNA binding domain, two Pur-repeat III form the intermolecular dimerization domain. C: A 
fit of three Pur-α I-II molecules into the Z-like envelope calculated from the data obtain from Pur-α I-III measurements of small angle X-ray 
scattering (SAXS). (Figures adapted from (Graebsch et al., 2009). 
 
1.3. Pur-α’s cellular functions 
Pur-α is a ubiquitous multifunctional protein that binds to both DNA and RNA and is known 
to regulate replication, transcription and translation. It has been shown that Pur-α can bind to 
single- and double-stranded nucleic acids that contain a GGN consensus motif. Pur-α also 
plays an important role in the transport of specific mRNAs to the dendrites in the developing 
brain. Besides being an essential neuronal factor, Pur-α is also involved in oncogenic 
transformation. In the following sections Pur-α’s cellular functions will be summarized. 
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1.3.1. Replication 
Initiation of replication requires unwinding of duplex DNA. It has been shown that Pur-α can 
bind to ssDNA and dsDNA and possesses DNA-helix-destabilizing activity (Darbinian et al., 
2001). Furthermore it associates with DNA sequences that are close to viral and cellular 
origins of replication (Darbinian et al., 2001; Gallia et al., 2000). There is also evidence that 
Pur-α might be involved in replication-dependent repair of DNA lesions, as Pur-α deficient 
cells show enhanced sensitivity to the DNA replication inhibitor hydroxyurea and to the 
DNA-crosslinking anti-tumor drug cis-platin (Kaminski et al., 2008; Wang et al., 2007). 
 
1.3.2. Transcription 
Pur-α has been found to bind to the purine-rich region upstream of the human c-myc promoter 
(Bergemann and Johnson, 1992; Bergemann et al., 1992) and to regulate the transcription of 
more than 20 genes (reviewed in White et al., 2009). Important neuronal genes regulated by 
Pur-α are for example the myelin proteolipid protein 1 (Plp1) gene (Dobretsova et al., 2008) 
and the myelin basic protein (Mbp) gene (Darbinian et al., 2001; Haas et al., 1995) both 
responsible for myelination of nerve cells in the central nervous system (CNS). 
Pur-α-DNA binding results in formation of a multimeric complex accompanied by interaction 
with other transcription factors like SP1 (Tretiakova et al., 1999), YB1 (Kim et al., 2008), 
SP3 and Pur-β (Ji et al., 2007). SP1, for example, enhances the interaction of Pur-α with the 
Mbp promoter, thereby stimulating Mbp gene expression in glial cells (Haas et al., 1995; 
Tretiakova et al., 1999). Overexpression of Pur-α and SP1 in the CNS results in synergistic 
stimulation of MBP expression. 
Another target gene of Pur-α is mouse vascular smooth muscle (VSM) α-actin (Kelm et al., 
1997). Pur-α has been shown to bind to the purine-rich strand of the MCAT enhancer and 
interacts together with Pur-β and the mouse Y-box protein MSY1 (Kelm et al., 1997). 
Pur-α is also involved in regulation of several human viruses. It activates the early and late 
promoters of the JC (John Cunningham) polyomavirus and the HIV-1 (human 
immunodeficiency virus 1) LTR (long terminal repeat) (reviewed in White et al., 2009). 
Conversely, Pur-α was also reported to negatively regulate gene transcription including α-
actin, amyloid-β protein, CD43, fas, gata2 and somatostatin (White et al., 2009) and even its 
own gene by binding to its own promoter and preventing its transcription (Muralidharan et al., 
2001). 
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1.3.3. RNA transport and translational control 
Pur-α plays an important role in the transport of specific mRNAs to the dendrites in the 
developing brain. For example, Pur-α binds to mouse non-coding BC1 RNA and to its human 
counterpart BC200 RNA (Johnson et al., 2006; Kobayashi et al., 2000), which are expressed 
almost exclusively in the nervous system and are distributed in neuronal dendrites as 
RNA:protein complexes. Pur-α has been suggested to link the BC1 RNA complex to 
microtubules (Ohashi et al., 2000). The Pur-α binding site of the BC1 RNA lies within its 5’ 
proximal region and contains G/U- rich residues.  
Consistently, PURA -/- mice show disturbed localization of the protein Staufen and FMRP 
(fragile X mental retardation protein). Both are involved in specific mRNA transport in 
dendrites (Johnson et al., 2006). RNA immunoprecipitation experiments indicated that FMRP 
and Pur-α interact simultaneously with Map2 RNA, a dendrite-specific protein. 
In addition, RNA interference experiments revealed that Pur-α is essential for mRNP 
transport (Kanai et al., 2004). 
Aumiller et al. analyzed the localization of Pur-α in Drosophila oocytes and showed that Pur-
α appears to associate with the oocyte mRNA transport system, and to shuttle between 
nucleus and cytoplasm. Actually, dimerization of Pur-α is necessary to achieve optimal 
transport into the oocyte (Aumiller et al., 2012). 
Data from mouse brain support a role for Pur-α in dendritic protein translation and dendrite 
maturation, by regulating the neuronal levels of RhoA, a GTPase, critical for mRNA 
translation and dendritic maturation including subcellular compartmentalization and turn over. 
 
1.3.4. Pur-α knock out mice 
The crucial role of Pur-α for postnatal brain development is highlighted by its genetic 
inactivation in the mouse model. PURA -/- mice appear normal at birth, but after 2 weeks they 
develop neurological problems and die after 4 weeks (Khalili et al., 2003). These mice show 
fewer cells in the brain cortex, hippocampus and cerebellum as a consequence of decreased 
proliferation of the precursor cells. Depletion of Pur-α also causes pathological development 
of the astrocytes and oligodendrocytes. In addition, the number of synapses is significantly 
reduced in the hippocampus. Hokkanen et al. generated a Pur-α-deficient mouse model that 
allowed studying Pur-α’s impact on brain growth and hippocampal and cerebellar 
development from newborn to the age of 6 months (Hokkanen et al., 2012). In contrast to 
Khalili et al. they observed enhanced proliferation of neuronal precursor cells and concluded 
that this may reflect a protraction of the brain development. Moreover, their PURA -/- mice 
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showed reduced expression of the neuron-specific cytoskeletal protein Map2 (microtubule-
associated protein 2) and pathological hyperphosphorylation of axonal proteins. The adult 
Pur-α deficient mice suffered from continuous tremor, ataxia and showed enlarged brain size, 
which are the phenotypical aspects of the fragile X-associated tremor/ataxia syndrome 
(FXTAS). Further studies indicate that the PURA -/- mice showed altered dendritic localization 
of Staufen and FMRP, both being essential for specific mRNA transport to the dendrites 
(Johnson et al., 2006). Additionally, in Pur-α knockout mice RhoA levels are reduced and 
dendrite maturation is impaired (Mishra et al., 2013). 
 
1.3.5. Pur-α and cancer 
Several lines of evidence suggest that Pur-α is a major player in cell cycle control and 
oncogenic transformation. Pur-α binds to regulatory proteins such as retinoblastoma protein, 
E2F-1, cyclin A/Cdk2, etc. (Darbinian et al., 2004; Itoh et al., 1998; Johnson et al., 1995). 
Intracellular levels of Pur-α vary during the cell cycle, declining at the onset of S-phase and 
peaking during mitosis. Pur-α causes cell cycle arrest at either G1/S or G2/M phase (Itoh et al., 
1998). Experiments showed that ectopic overexpression of Pur-α, e.g. in glioblastomas, 
suppresses their growth, whereas depletion of Pur-α have been reported in myelodysplastic 
syndrome and prostate cancer (Inoue et al., 2008; Johnson et al., 1995; Lezon-Geyda et al., 
2001). Taken together, these results indicate that Pur-α might act as a tumor suppressor 
protein. 
 
Thus, Pur-α is a multifunctional protein binding to ss/dsDNA and RNA and is involved in 
many cellular processes from replication and transcription to mRNA transport and translation 
in neurons. Hence, a better understanding of Pur-α binding mode to nucleic acids would help 
to comprehend the role of Pur-α in its various cellular functions and its role in cancer 
development. 
 
 
1.4. Nucleotide repeat expansion diseases 
Trinucleotide repeat disorders form a significant group of at least 16 neurologically inherited 
diseases such as Huntington disease and inherited ataxias (Orr and Zoghbi, 2007). Several 
cases have been reported where expansions of CAG trinucleotide repeats within coding 
regions of genes result in proteins with long repeating stretches of glutamine. Polyglutamine 
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peptides show enhanced propensity to form aggregates and large inclusions, resulting in 
neuronal dysfunction, neurodegeneration and neuronal loss (Ross and Poirier, 2004).  
Also abnormal trinucleotide expansions in non-coding regions of genes can lead to severe 
clinical symptoms. For instance, the fragile X syndrome (FXS) (Oostra and Willemsen) is 
caused by abnormal trinucleotide expansions in the 5' untranslated region (5’UTR) of the 
fmr1 gene. Myotonic dystrophy type 1 (DM1) is a dominant disorder caused by CTG repeat 
expansion within the 3’ untranslated region (3’UTR) of the dystrophia myotonica-protein 
kinase (dmpk) gene. Investigations on DM1 have demonstrated that repeat expansions can be 
pathogenic at the RNA level (Day and Ranum, 2005; Liquori et al., 2001). Similar evidence 
now supports that an RNA gain-of-function mechanism may also be involved in the 
pathogenesis of the non-coding expansion disorder FXTAS (Oostra and Willemsen, 2009). 
 
1.4.1. Fragile X syndrome 
Fragile X syndrome (FXS) is the most common monogenetic form of autism and intellectual 
disability and was the first example of a trinucleotide repeat expansion disease (Oostra and 
Willemsen, 2009). In 1991 the responsible gene was identified and named fragile X mental 
retardation 1 gene (fmr1) (Verkerk et al., 1991). The gene is located on the X-chromosome 
(Xp27.3), is highly expressed in the brain and testis (Devys et al., 1993) and encodes for the 
FMR1 protein (FMRP). Although ubiquitously expressed, the FMRP is an essential neuronal 
protein that regulates translation of hundreds of mRNAs, mostly involved in synaptic 
plasticity (Darnell and Richter, 2012). FXS is less severe in affected females, presumably 
because of X inactivation (Kaufmann et al., 1999; Tassone et al., 1999). Many affected 
females have some form of learning difficulties and behavioral problems (Hull and Hagerman, 
1993). For males the prevalence for FXS is estimated at 1/6,000 to 1/4,000 in the general 
population (Turner et al., 1996; Youings et al., 2000). 
FXS is caused by an expansion of a CGG repeat in the 5’UTR of fmr1. In the normal 
population the repeat length ranges from 5-54 CGGs. Patients with FXS show an expansion 
of more than 200 CGG repeats (termed full mutation range) leading to a transcriptional shut 
down of the gene and a lack of FMRP (Figure 1.2). Suppression of FMRP expression can be 
due to DNA- or/and RNA-mediated silencing. One scenario is that CGG repeat DNA can 
form hairpin structures, which trigger their own hypermethylation at the cytosine bases by 
DNA methyltransferases, as shown by in vitro experiments of Smith et al. (Smith et al., 1994). 
Another model suggests that repeat-binding proteins, for example transcription factors, form 
protein aggregates and thereby prevent transcription (Bulut-Karslioglu et al., 2012). An RNA-
mediated mechanism of gene silencing has been suggested by Colak et al. (Colak et al., 2014). 
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In this model, the CGG-repeat fmr1 mRNA hybridizes with the complementary DNA strand 
and thereby silences the fmr1 promoter. Furthermore, unusual hairpins within the CGG-repeat 
mRNA might form and become a substrate for the enzyme Dicer, facilitating RNA-induced 
silencing (Handa et al., 2003; Usdin et al., 2014). 
 
Figure 1.2 Fragile X syndrome. (Left) In the normal population 
(wild type) the CGG-repeat length in the 5’UTR of the fmr1 gene 
ranges from 5-54 repeats. The gene becomes normally transcribed, 
incorporated into mRNPs and translated into the FMRP. (Right) 
When CGG repeats expand up to more than 200 repeats, the fmr1 
gene becomes hypermethylated and transcriptionally inactivated. 
FMRP is not expressed in the fragile X syndrome. (Figure adapted 
from Willemsen et al., 2011). 
 
 
 
 
 
 
 
1.4.2. FXTAS 
The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset (over 50 years) 
neurodegenerative disease, which is uncoupled from the FXS. Both disorders involve repeat 
expansion in the fmr1 gene, but the clinical features and the molecular mechanism behind 
each disease is different (Hagerman and Hagerman, 2007; Hagerman et al., 2001; Jacquemont 
et al., 2003). However an overlap of these two diseases occurs when the full mutation (>200 
CGG repeats) is partially or completely unmethylated or there is a high mosaicism in FXS. In 
this case FXS patients might also develop FXTAS. 
FXTAS has been described in 2001 and is associated with a wide range of clinical features, 
such as tremor, ataxia, parkinsonism, dementia, neuropathy, executive function defects and 
disautonomia (reviewed in Hagerman and Hagerman, 2007). Life expectancy is between 5-25 
years after onset of symptoms (Seritan et al., 2008), whereby CGG repeat size correlates with 
age of onset and age of death (Leehey et al., 2007; Ludwig et al., 2014). 
FXTAS is one of the most common single-gene disorders leading to neurodegeneration in 
males. It is caused by moderate expansions (55-200 repeats) of a CGG trinucleotide in the 
5’UTR of the fmr1 gene (premutation range). 200 or more CGG repeats (full mutation) in the 
same gene cause FXS. About 1 in 800 males and 1 in 260 females of the general population 
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are carriers of fmr1 premutations (Dombrowski et al., 2002). Nearly 1 in 3000 men have a 
lifetime risk of developing FXTAS (Jacquemont et al., 2003). The penetrance in females is 
much lower and female carriers only infrequently develop FXTAS. Approximately 4% of all 
female carriers develop milder FXTAS-related symptoms (Coffey et al., 2008) and 20% 
suffer from premature ovarian failure (POF) (Cronister et al., 1991).  
The major neuropathological hallmark for FXTAS is eosinophilic, ubiquitin-positive, 
intranuclear, neuronal and astrocytic inclusions located in broad distribution throughout the 
brain (Greco et al., 2006; Iwahashi et al., 2006) and other organs such as adrenals, thyroid, 
heart, Leyding cells and pancreas (reviewed in Muzar and Lozano, 2014). Numbers of 
inclusions strongly correlate with the size of the CGG repeats. Analyses on the inclusions 
revealed association with fmr1 mRNA and more than 20 proteins, including histones, 
intermediate filaments, microtubule components, myelin associated proteins. Among these 
proteins are the stress related protein αB-crystallin, the RNA-binding protein heterogeneous 
nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) (Iwahashi et al., 2006; Sofola et al., 2007), 
the splicing factor Sam68 (Sellier et al., 2010) and the DNA/RNA binding protein Pur-α (Jin 
et al., 2007). In addition it was revealed that no single protein is predominant or accounts for 
more than 10% of the protein mass (Iwahashi et al., 2006). 
Sellier and colleagues proposed a mechanism, in which Sam68-responsive splicing is altered 
in FXTAS patients (Sellier et al., 2010). Its depletion in a mouse model leads to motor 
coordination defects (Lukong and Richard, 2008). It was found that Sam68 is sequestered by 
mRNAs containing expanded CGG repeats and thereby loses its splicing-regulatory function 
(Sellier et al., 2010). The same study showed that recruitment of Sam68 is a rather late event 
during FXTAS particle formation. Therefore its interaction with CGG repeats is thought to be 
indirect. 
Another working hypothesis was that inclusions arise in part of impeded proteasomal 
degradation and subsequently accumulation of multiple polyubiquitinated protein species. 
However, it was shown that only a small number of proteins appear to be ubiquitinated and 
that polyubiquitination is unlikely (Iwahashi et al., 2006). These observations argue against 
the aggregation models that occur in many expanded CAG (polyglutamine) repeat disorders, 
in which the misfolded and/or polyubiquitinated proteins fail proteasomal degradation. 
 
1.4.2.1. RNA toxicity – sequestration model 
Yrigollen et al. observed that within the CGG repeat track of the fmr1 gene usually 1-3 AGG 
interruptions are found in the normal population. These interruptions occur after 9 or 10 
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uninterrupted CGG repeats. However, none or only one AGG interruption is found in 
premutation carriers, and the length of pure CGG repeats strongly correlates with fmr1 mRNA 
levels (Yrigollen et al., 2011). Furthermore, Kiliszek et al. could show that CGG-RNA repeats 
form hairpins with non-canonical GG pairs that are thermodynamically more stable than CAG 
and CUG repeats (Kiliszek et al., 2011). 
Although the molecular pathogenesis of FXTAS remains unclear, an RNA gain-of-function 
mechanism is generally assumed to be the mechanistic trigger of this disease. This is in part 
based on the observation that levels of premutation fmr1 mRNA are elevated 5-8-fold, while 
FMRP levels are decreased due to inefficient translation (Ludwig et al., 2014; Pretto et al., 
2014). Also FXTAS has not been observed among older adults with full mutation alleles in 
whom the fmr1 gene is silenced (Iwahashi et al., 2006). However recent evidence supports 
that both FMRP deficits and elevated fmr1 mRNA levels might contribute to the 
pathomechanism of FXTAS. 
Elevated mRNA levels can be caused by different events. For instance, histones at the fmr1 
promoter with FXTAS premutation show increased acetylation, which in turn leads to 
increased gene transcription (Todd et al., 2010). Another reason for elevated mRNA levels 
was suggested by Wang et al. (Wang et al., 1996). They showed that CGG-repeats exclude 
nucleosomes in vitro, which may facilitate the binding of transcription factors in vivo. 
Additionally, CGG-repeats form so-called R-loops, which lead to chromatin decondensation 
and increased transcription (Loomis et al., 2014; Powell et al., 2013). 
Already in 2003 Jin et al. have proposed a mechanism by which elevated levels of CGG-
repeat RNA can cause neurodegeneration. Here, CGG-repeat binding proteins become 
sequestered from their normal functions by the abundant premutation RNA (Jin et al., 2003) 
(Figure 1.3). Several of such RNA-binding proteins have been uncovered, including Pur-α, 
Rm62, CUGBP1, hnRNP A2/B1, Sam 68 and DROSHA-DGCR8 (reviewed by Lozano et al., 
2014) that are also present in FXTAS inclusions. Sequestration of these proteins might lead to 
altered transcription, RNA processing, RNA trafficking causing altered protein conformation 
and function. 
Antisense transcripts of the fmr1 gene might also contribute to RNA toxicity. Similar to fmr1, 
the antisense fmr1 (asfmr1) transcript is elevated in permutation carriers and is not expressed 
in FXS, suggesting that the antisense transcription may contribute to the pathogenesis of 
FXTAS and FXS. In addition, the asfmr1 transcript exhibits premutation-specific alternative 
splicing that might contribute to disease-related abnormalities (Ladd et al., 2007). 
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Figure 1.3 Schematic representation of the RNA gain-
of-function mechanism proposed for FXTAS. The 
premutated fmr1 gene causes enhanced transcription and 
therefore elevated levels of the fmr1 mRNA. Though, the 
expanded CGG repeats hamper the translation at the 
ribosomes leading to slightly lower levels of FMR1 protein. 
Amongst others, CGG-binding proteins like Pur-α or 
hnRNP A2/B1 become recruited to the fmr1 mRNA, which 
leads to the formation of intranuclear inclusions and likely 
results in the pathology of FXTAS. (Figure adapted from 
Oostra and Willemsen, 2009). 
 
 
 
 
1.4.2.2. RAN translation – homopolymeric proteins 
RAN (repeat-associated non-ATG) translation occurs across long, hairpin forming repeats and 
was first discovered in SCA8 (spinocerebellar ataxia 8), a neurodegenerative trinucleotide 
repeat-expansion disease (Daughters et al., 2009). The sca8 gene carries a CTG/CAG repeat 
expansion in its 3’UTR, which is translated in an ATG-independent manner in all three 
reading frames, encoding homopolymeric (poly-glutamine, poly-alanine and poly-serine) 
proteins (Zu et al., 2011). RAN translation has also been shown for the myotonic dystrophy 
type 1 gene, which also contains a trinucleotide repeat expansion (CTG) in the 3’UTR and 
results in poly-glutamine proteins (Zu et al., 2011).  
RAN translation in at least two out of three reading frames has also been found for FXTAS. 
Todd et al. demonstrated that non-canonical translation of CGG-repeat expansions in FXTAS 
results in expression of polyglycine and polyalanine-containing products. Theses products are 
toxic in Drosophila and in human cell lines and induce intranuclear inclusion formation. 
Furthermore, the polyG and polyA-proteins are also present in FXTAS patient brains (Reddy 
and Pearson, 2013; Todd et al., 2013). 
 
1.4.2.3. Therapy 
There are no effective targeted therapies for FXTAS treatment, only medications to alleviate 
some of the symptoms. Memantine (FDA approved drug for Alzheimer’s disease) is the only 
targeted trial for FXTAS. It reduces symptoms by selectively blocking the excitotoxic effects 
caused by abnormal transmission of glutamate in neurons. Patients treated with memantine 
showed improvements in cued-recall (Yang et al., 2014). Beta-blocker medications, such as 
propranolol and primidone have reduced tremor in some FXTAS patients (Hagerman et al., 
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2012; Hagerman et al., 2008; Leehey, 2009). Current research focuses on preventing the 
neurobiological abnormalities in FXTAS with pharmaceutical compounds. The neurosteroid 
allopregnanolone was shown to ameliorate clustered burst firing in hippocampal permutation-
neurons (Cao et al., 2012) and is a potential treatment for FXTAS. Other approaches for 
treatment focus on the molecular mechanisms of the disease. To understand the molecular 
causes of FXTAS, animal models (mouse, Drosophila) have been developed (Berman et al., 
2014; Sofola et al., 2007). 
 
1.4.3. ALS/FTLD 
ALS (amyotrophic lateral sclerosis) is a late-onset neurodegenerative disease with symptoms 
occurring mostly at the age of 40-60 years and affecting men more frequently than women 
(reviewed by McCombe and Henderson, 2010). Juvenile ALS is rare. However, the disease 
may start early in life and show clinical features at a much later stage. Most patients 
diagnosed with ALS die within 3-5 years after disease onset. ALS is the most common motor 
neuron disease. The key features of the disease are muscle atrophy and weakness, 
fasciculation and spasticity due to degeneration of lower motor neurons in the brain stem and 
spinal cord, and loss of the upper motor neurons in the motor cortex (Horton et al., 1976; 
Robberecht and Philips, 2013). Neurons of the prefrontal and temporal cortex are also 
affected in ALS, leading to frontotemporal dementia (FTD) in about 15 % of patients (also 
known as frontotemporal lobar degeneration [FTLD]) (Ringholz et al., 2005). FTLD is the 
second most common dementia after Alzheimer’s disease (Harvey et al., 2003; Van 
Langenhove et al., 2012) and is clinically, pathologically and mechanistically linked to ALS 
(Ringholz et al., 2005; Wheaton et al., 2007). Post-mortem examinations of ALS and FTLD 
patients revealed nuclear and cytoplasmic inclusions of aggregated proteins in neurons as the 
major pathological hallmark (Neumann et al., 2006). FTLD is classified based on the main 
protein component (Tau, TDP, FUS and UPS) of inclusions found in cortical neurons 
(reviewed in Ling et al., 2013). TAR DNA-binding protein 43 (TDP43) is the major 
ubiquitinated protein present in FTLD inclusions, which is similar to what is found in motor 
neurons of ALS patients (Arai et al., 2006; Neumann et al., 2006). 
With the identification of a disease-causing hexanucleotide (G4C2) repeat expansion mutation 
in the C9orf72 (chromosome 9, open reading frame 72) gene, another molecular link between 
ALS and FTLD was established (DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
Moreover, Pur-α was found to bind G4C2-repeat RNA. Expression of mutant G4C2-repeat 
RNA in mouse motoneuronal-like NSC34 and HeLa cells affected the distribution of Pur-α 
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and FMRP (Rossi et al., 2015). Repeat expansions of the C9orf72 resembles CGG repeats of 
the fmr1 gene. Both repeat RNAs cause sequestration of RNA-binding proteins, inclusion 
formation and in particular mislocalization of Pur-α (Jin et al., 2007; Sofola et al., 2007). 
ALS is classified into two categories: familial ALS (FALS) and sporadic ALS (SALS). 90-
95 % of ALS cases are sporadic and do not have an obvious family history. FALS is mostly 
inherited in an autosomal dominant way and only rarely X-linked or recessive (Andersen and 
Al-Chalabi, 2011; Pramatarova et al., 1995). 
 
1.4.3.1. Protein toxicity/aggregation 
Protein aggregates are the hallmark of many neurodegenerative diseases. The initiating event, 
which may induce ALS is aggregation of mutant proteins like SOD1 (superoxide dismutase 1), 
UBQLN2 (ubiquillin-2), VCP (vasolin-containing protein), TDP43 (Tar-DNA binding 
protein) or FUS/TLS (fused in sarcoma/translocated in liposarcoma) disrupting the normal 
protein homeostasis, intracellular transport, cytoskeletal architecture and mitochondrial 
function (reviewed in Robberecht and Philips, 2013). These defects induce cellular stress and 
in turn lead to axonal retraction and death of motor neurons (Bendotti et al., 2012; Saxena and 
Caroni, 2011). 
20% of FALS is caused by a mutation in SOD1. Most mutations are missense mutations, 
which lead to misfolding of the protein. Mutant SOD1 protein usually becomes ubiquitinated 
and subsequently degraded by the proteasome, however, in ALS mutant SOD1 fails to be 
degraded and even impairs the proteasomal pathway as well as autophagy (Basso et al., 2006). 
Mutant SOD1 accumulates as oligomers and later as aggregates thereby causing stress 
response followed by loss of motor neurons. 
UBQLN2 belongs to the ubiquitin-like protein family and delivers ubiquitinated proteins to 
the proteasome. Mutations in UBQLN2 occur in X-linked FALS, FALS, FTLD and SALS. 
UBQLN2 has been found in skein-like inclusions within motor neurons and the spinal cord 
together with TDP43 and FUS/TLS (Deng et al., 2011; Williams et al., 2012). Mutations in its 
conserved proline-rich region (P497H, P497S, P506T, P509S and P525S) have been shown to 
be associated with ALS and lead to overall impairment of protein degradation (Deng et al., 
2011; Gellera et al., 2013; Williams et al., 2012). 
Another key factor for proteasomal protein degradation and autophagy is VCP. Being an 
ubiquitin-sensitive chaperone, VCP unfolds and disassembles protein complexes and thereby 
enables degradation or recycling. Depletion of VCP leads to protein accumulation and 
immature autophagosomes (Ju et al., 2009; Tresse et al., 2010). Johnson et al. identified 
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mutations in the N-terminal region of VCP from ALS patients, which impair the fusion of 
lysosomes with autophagosomes and thereby disrupt autophagy (Johnson et al., 2010; Ju et al., 
2009; Watts et al., 2004). 
FUS/TLS and TDP43 are the major protein components of pathogenic inclusions observed in 
90 % of ALS and >50 % of FTLD (Arai et al., 2006; Neumann et al., 2006). Both, TDP-43 
and FUS/TLS are RNA-binding proteins that are involved in mRNA splicing, transport and 
translation regulation. Defects in RNA processing were therefore thought to be the major 
cause for ALS and FTD. Normally TDP43 shuttles from the nucleus to the cytoplasm and 
associates with RNA transport complexes (Ayala et al., 2008; Kiebler and Bassell, 2006; 
Zinszner et al., 1997). Mutations in TDP43 cause a shift of nuclear to cytoplasmic localization 
of TDP43 and an increase of aggregation propensity (Johnson et al., 2009). As a result TDP43 
is no longer abundant in the nucleus (loss of function), which induces abnormal RNA 
processing. Elevated levels of mutant TDP43 in the cytoplasm tend to aggregate and might in 
turn sequester other proteins and RNAs (gain-of-function) and therefore contribute to the 
pathomechanism of ALS. 
FUS/TLS also shuttles from the nucleus to the cytoplasm. FUS mutations have been found in 
ALS patients, who also showed FUS-positive inclusions (Kwiatkowski et al., 2009; Sun et al., 
2011). All mutations in FUS/TLS found in ALS patients are missense mutations that affect 
the C-terminal domain containing the NLS (nuclear localization signal) or the glycine-rich 
region (reviewed in Lagier-Tourenne et al., 2010). These mutations often interrupt the 
interaction with transportin, which mediates nuclear import of FUS and lead to accumulation 
of FUS into stress granules that may form inclusions (Dormann et al., 2012; Dormann et al., 
2010). Similar to TDP43, it is still unknown if mutant FUS/TLS contributes to ALS by a toxic 
gain-of-function mechanism (aggregation in the cytoplasm), a loss-of-function mechanism 
(depletion of FUS in the nucleus) or both. 
 
1.4.3.2. RNA toxicity 
Another disease-causing mechanism found in ALS and FTLD are the hexanucleotide (G4C2) 
repeat expansion mutations located in the first intron of the C9orf72 gene. The C9orf72 gene 
is mostly expressed in the central nervous system (Renton et al., 2011). In the normal 
population the C9orf72 gene bears two to five G4C2-repeats and never exceeds 30 repeats. 
ALS patients show an expansion of ~600-2000 G4C2 repeats (DeJesus-Hernandez et al., 
2011; Gijselinck et al., 2012; Renton et al., 2011). ALS caused by C9orf72 mutations is 
dominantly inherited. Abnormal repeat expansions are found in 80 % of familial ALS-FTLD, 
20-50 % of FALS, 5-10 % of SALS, 10-30 % of FTLD cases and are therefore the most 
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common cause of ALS and FTLD (Boeve and Graff-Radford, 2012; Chio et al., 2012; 
Mahoney et al., 2012). The C9orf72 gene comprises 12 exons, of which 2 are non-coding. By 
normal alternative splicing, 2 protein-coding mRNAs are transcribed (Renton et al., 2011). 
The function of the protein isoforms is still unknown, although they are highly conserved in 
plants, fungi and animals. However, Drosophila melanogaster lacks the C9orf72 gene, but 
expresses a structural homologue called (differentially expressed in normal and neoplastic 
cells) DENN-like protein, which plays a role in synapse formation and function (Levine et al., 
2013; Zhang et al., 2012). 
There are three pathogenic mechanisms that could contribute to the pathogenesis of 
ALS/FTLD linked to C9orf72 mutations: Reduced expression of the C9orf72 protein (loss of 
function), accumulation of repeat-RNA trapping RNA-binding proteins and thereby 
disrupting RNA processing (gain of RNA toxicity) and accumulation of toxic poly-dipeptides 
by RAN translation (gain of protein toxicity). The leading pathological mechanism is still 
unknown. 
ALS patients with a C9orf72 expansion showed a reduction of C9orf72 mRNA levels by 
50 % due to partial or complete silencing of the expanded allele. However reduction of 
protein level has not been demonstrated (DeJesus-Hernandez et al., 2011; Gijselinck et al., 
2012). 
Neuronal, intranuclear RNA foci containing C9orf72 hexanucleotide repeat RNA have been 
detected by fluorescence in situ hybridization experiments using a G4C2 probe (DeJesus-
Hernandez et al., 2011; Rossi et al., 2015). These RNA foci might trap RNA-binding proteins, 
which in turn cannot fulfill their normal functions leading to disruption in RNA processing. 
Furthermore, protein binding might be enforced by G-quadruplexes formed by G4C2-repeats 
(Haeusler et al., 2014). 
 
1.4.3.3. RAN translation - dipeptide repeat proteins 
Recent studies have demonstrated that RAN translation also occurs at the C9orf72 transcript. 
Other than FXTAS, the G4C2-repeat RNA generates dipeptide repeat (DPR) proteins 
(glycine-proline, glycine-arginine and glycine-alanine). These polydipeptides can be detected 
with antibodies in neuronal aggregates of C9orf72-linked ALS/FTLD patients (Mori et al., 
2013). Glycine-alanine dipeptides were the most abundant proteins detected in inclusions of 
the cerebellum, hippocampus and other brain regions of postmortem patients. The inclusions 
were similar in shape and abundance to typical ALS/FTD inclusions. This data suggests that 
dipeptide-repeat proteins generated by RAN translation contribute to ALS/FTLD 
pathogenesis. 
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1.4.3.4. Therapy 
It has been shown that chronic glutamate excitotoxicity may accumulate to toxic levels and 
contribute to neuronal death in ALS. Riluzole, an inhibitor of presynaptic glutamate release, is 
the only currently FDA-approved drug for treatment of ALS. However, riluzole can only 
prolong the patient’s life for a few months (Rothstein, 1996). 
One target for therapeutic treatment is the SOD1 protein. Anti-mutant SOD1 antibody and 
anti-sense oligonucleotides targeting Sod1 mRNA were shown to reduce the synthesis of the 
pathogenic mutant SOD1 protein in transgenic mice and rats expressing human SOD1 (Ralph 
et al., 2005; Raoul et al., 2005; Smith et al., 2006). Reduction of mutant SOD1 protein slowed 
down the disease progression and is therefore an appealing approach for disease treatment 
(Gros-Louis et al., 2010). 
In general, decreasing aggregation of misfolded proteins, like mutant SOD1, could be one 
way to delay disease progression. Heat shock proteins play a crucial role in folding/unfolding 
of proteins and thereby protect cells against stress and apoptosis (reviewed in Li and 
Srivastava, 2004). Kieran et al. treated mice expressing human mutant SOD1, which is prone 
to aggregate, with arimoclomol. Arimoclomol induces the heat shock proteins Hsp70 and 
Hsp90 and thereby slows down protein aggregation and the progressive loss of motor neurons 
(Kieran et al., 2004). 
Another promising treatment for ALS represents transplantation of induced pluripotent stem 
cells (Robberecht and Philips, 2013) generated from fibroblasts of the ALS patient himself. 
These reprogrammed pluripotent cells can differentiate again into all cell types and therefore 
replace diseased motor neurons (Dimos et al., 2008; Glass et al., 2012). 
 
 
1.5. Pur-α in FXTAS and ALS/FTLD 
Pur-α is a DNA/RNA binding protein preferentially binding to purine-rich sequences (GGN 
motif), which can be found in both disease-related genes fmr1 (FXTAS) and C9orf72 (ALS-
FTLD). Electrophoretic mobility shift assays (EMSA) with recombinant protein showed that 
Pur-α binds directly to FXTAS-linked CGG-repeat DNA and RNA with reasonable affinity 
(Graebsch et al., 2009). Additionally, Pur-α was pulled down from different tissues (mouse 
and human neurons, COS7 and HeLa cells) using biotinylated CGG- or G4C2-repeat RNA 
(Jin et al., 2007; Rossi et al., 2015; Sofola et al., 2007). Furthermore, Pur-α has been found to 
co-localize in FXTAS- and ALS/FTLD-related nuclear and cytoplasmic inclusions of repeat-
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RNA expressing cell lines (COS7, HeLa), animal models (mouse, Drosophila) and patients 
(Jin et al., 2007; Sofola et al., 2007; Xu et al., 2013). 
Being an important neuronal factor, sequestration of Pur-α into FXTAS and ALS/FTLD 
inclusions and thereby loss of function might cause disturbance of replication, transcription, 
mRNA transport and translation leading to neuronal cell death. Overexpression of Pur-α has 
been shown to rescue the CGG- and G4C2-mediated eye neurodegeneration phenotype of 
FXTAS and ALS in the fly model (Jin et al., 2007; Sofola et al., 2007). Pur-α also rescued 
cell viability when co-expressed in mammalian neuronal cells together with G4C2-repeat 
RNA (Xu et al., 2013). 
Qurashi et al. showed that many Pur-α interaction partners are involved in CGG-repeat RNA-
mediated neuronal toxicity. One interaction partner is Rm62, the Drosophila ortholog of p68 
RNA helicase that is implicated in transcriptional regulation, pre-mRNA splicing, RNA 
interference and nucleo-cytoplasmic shuttling. It was shown that CGG-repeat RNA 
expression in Drosophila decreased the expression of Rm62, leading to nuclear accumulation 
of mRNAs involved in stress response (Qurashi et al., 2011). Notably, this process might be 
mediated by the interaction with Pur-α, which is affected in its localization by C9orf72 
expression, and might therefore also play a role in C9orf72-mediated neurodegeneration in 
Drosophila (Xu et al., 2013). 
 
Taken together, there are multiple evidences that Pur-α plays a crucial role in the pathogenesis 
of several neurodegenerative diseases. Therefore, insights into the molecular interactions of 
Pur-α with disease-related repeat-RNA would significantly help to elucidate its role in 
ALS/FTLD and FXTAS. 
 
 
1.6. Objectives 
This study consists of two parts. The first part focuses on the molecular principles of Pur-α’s 
binding to nucleic acids and its normal cellular function. The second part deals with Pur-α’s 
role in neurodegenerative diseases.  
The first aim of this study was to obtain the crystal structure of a Pur-α/nucleic acid co-
complex to understand Pur-α’s binding mode, complex stoichiometry and potential 
differences between DNA- and RNA-binding. Since Pur-α is a multifunctional protein, results 
could then be used to further clarify its cellular functions and furthermore its role in 
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neurodegenerative diseases. Additional structural methods, like NMR and SAXS, as well as 
biochemical assays have been used to accomplish this task. 
Pur-α is an important neuronal factor that is involved in replication and transcription of 
several neuronal genes. Mice with disruption in both alleles of the Pur-α gene die after birth 
within 4 weeks, suffering from severe neurological defects. By establishing a stable cell line 
expressing GFP-tagged Pur-α, I wanted to perform Chip-Seq (Chromatin 
Immunoprecipitation DNA Sequencing) experiments that could reveal which genes become 
activated by Pur-α, whether they share a consensus sequence and if they can be classified into 
sub-categories. Findings would also contribute to understand why Pur-α deficient mice die 
after birth. 
 Pur-α has been shown to be involved in the pathomechanism of neurodegenerative diseases 
like ALS/FTLD and FXTAS. In order to understand Pur-α’s role in these diseases, the aim of 
this last part was to establish a stable cell line expressing normal and FXTAS-related CGG-
repeat RNA to identify proteins that directly bind to the CGG-repeat RNA and to validate if 
Pur-α is amongst these proteins. This way, findings for cells expressing normal and disease-
related repeat RNA could be compared. Furthermore, it would be possible to identify 
potential protein interaction partners of Pur-α in the disease context. 
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2. Results 
2.1. Structural and functional studies 
Pur-α is a ubiquitous multifunctional protein that binds to both DNA and RNA and is known 
to regulate replication, transcription and translation (reviewed in White et al., 2009; Gallia et 
al., 2000). Pur-α also plays an important role in the transport of specific mRNAs to the 
dendrites in the developing brain and is involved in transcription of several neuronal genes 
(Darbinian et al., 2001; Dobretsova et al., 2008; Haas et al., 1995). Besides being an essential 
neuronal factor, Pur-α has been implicated in the pathomechanism of the fragile X-associated 
tremor/ataxia syndrome (FXTAS), a heritable neurodegenerative disease caused by a 
moderate expansion of a CGG trinucleotide in the 5’UTR of the fragile X mental retardation 
1 (fmr1) gene (Jacquemont et al., 2003). Consistent with its role in FXTAS, Pur-α binds to 
single- and double-stranded nucleic acids that contain a GGN consensus motif (White et al., 
2009). To date Pur-α’s binding mode to DNA and RNA is unknown. Hence, different 
biochemical and biophysical analyses of Pur-α’s interaction with nucleic acids have been 
performed to comprehend the role of Pur-α in its various cellular functions. 
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2.1.1. Expression and purification of Drosophila and human Pur-α derivatives 
For all structural and functional studies Pur-α derivatives (Drosophila Pur-α repeat I-II (17 kDa), 
repeat I-III (26 kDa), repeat III (10 kDa) and human Pur-α repeat I-III (27 kDa)) were expressed 
and purified as described in chapter 4.13.1 and 4.13.2. After the final purification step by size 
exclusion chromatography with the corresponding buffer, pooling and concentrating of the peak 
fractions resulted in protein purities of ≥ 95 % for all constructs. This was monitored on 
chromatograms and SDS PAGE (Figure 2.1 A-D). 
 
 
 
Figure 2.1 Purification of Pur-α protein derivatives used in this study. A-D: Size exclusion chromatogram (blue) of the final purification 
step with the Superdex 75 10/300 GL column. Peak fractions (red dash) were pooled, concentrated and analyzed on SDS PAGE. A: D. 
melanogaster Pur-α I-II (17 kDa). B: D. melanogaster Pur-α I-III (26 kDa). C: D. melanogaster Pur-α III (10 kDa). D: human Pur-α I-III (27 
kDa). 
 
2.1.2. EMSA with Pur-α and DNA/RNA 
In order to assess if Pur-α has binding preference for ssDNA or RNA EMSA experiments were 
performed with the nucleic-acid binding domain of Drosophila Pur-α (repeat I-II) and 
radioactively labeled DNA or RNA oligonucleotides (24 nt) of identical sequence. The MF0677 
sequence was chosen as a physiological Pur-α target found upstream of the human c-myc gene 
(Haas et al., 1993; Haas et al., 1995)(Figure 2.2 A). The CGG-repeat sequence was chosen 
because Pur-α has been found in FXTAS inclusions (Jin et al., 2007; Sofola et al., 2007) and 
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binds to the CGG repeats at the 5’UTR of the fmr1 mRNA. When comparing the binding affinity 
for ssDNA and RNA of the same sequence, only a slight difference is visible (Figure 2.2 A left 
and right; B left and right). For both nucleic-acid sequences Pur-α has a slightly stronger affinity 
to ssDNA than to RNA. However, the affinity for the physiological Pur-α target MF0677 is much 
higher (KD ~200 nM) than for the disease-related CGG-repeat sequence (KD ~2 µM) (Figure 2.2 
compare A and B; KD estimated from EMSAs). In all EMSA experiments aggregation and 
therefore additional shifts were detectable at higher protein concentrations. 
 
 
Figure 2.2 Pur-α I-II binds with similar affinities to DNA and 
RNA. Radioactive EMSA experiments with D. melanogaster 
Pur-α I-II. A: Pur-α I-II binds to MF0677 ssDNA (left) and 
ssRNA (right) with similar affinity. B: Pur-α I-II binds to CGG-
repeat ssDNA (left) and RNA (right) also with similar affinity, 
but less strong than to the MF0677 sequence. 
 
 
 
 
 
 
 
 
 
2.1.3. NMR with Pur-α and DNA/RNA 
To further examine Pur-α’s binding mode to nucleic acids, NMR titration experiments were 
performed with Drosophila Pur-α I-II and DNA/RNA oligonucleotides. 15N-labeled Pur-α I-II 
was expressed and purified as described in chapter 4.13.1. and 4.13.2. The size exclusion 
chromatogram and SDS PAGE showed that the protein was pure and stable in NMR buffer 
(Figure 2.3 A). The aim was to compare DNA with RNA binding and to identify which 
residues are involved in interaction with nucleic acids and if RNA differs from DNA binding. 
Additionally, the stoichiometry of the protein-nucleic acid-complex should to be determined. 
However, since most chemical shift perturbations experienced an intermediate exchange 
regime throughout the titration steps, saturation and stoichiometric ratio could not be 
determined. Other problems occurred with the high protein concentration (50 µM) and buffer 
requirements (low pH, low salt) needed for NMR measurements. Under these conditions the 
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protein/DNA complex tended to aggregate and precipitate while measuring. Therefore, NMR 
experiments could not be used for stoichiometry determination. 
The 1H15N HSQC spectrum of Pur-α alone was nicely dispersed. However, initial RNA- and 
DNA-titration experiments with the MF0677 and CGG oligomers (24 nt) used in EMSA 
experiments (chapter 2.1.2) at the high concentrations required for NMR measurements, 
resulted in protein precipitation. This issue was resolved by performing titrations with short 
5’-GCGGA-3’ 5mer DNA and RNA fragments. Such short GGN motif RNA and DNA 
oligonucleotides still bound to Pur-α with reasonable affinity (Figure 2.3 B), but did not 
induce precipitation. Addition of both oligonucleotides resulted in similar chemical shift 
perturbations, regardless of whether it was ssDNA or RNA (Figure 2.3 C and D). Also, the 
spectra revealed that binding most likely occurs at the glutamine/asparagine/arginine side 
chains, as well as at some backbone residues. In summary, the NMR titration experiments 
suggest similar binding modes of Pur-α for DNA and for RNA involving identical residues in 
both cases. 
 
 
 
 
Figure 2.3 Pur-  I-II is stable in NMR buffer and binds to short GGN (5mer) oligonucleotides. A: Size exclusion chromatogram (blue) 
of the final purification step of 15N-labeled Pur-  I-II with the Superdex 75 10/300 GL column in NMR buffer. The protein purity was 
verified by SDS PAGE. B: EMSA with unlabeled Drosophila Pur-  I-II and fluorescent-labeled 5’-GTGGA-3’ ssDNA (5 nt). 
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Figure 2.3 NMR titration experiments show that Pur-α’s binding mode to DNA and RNA is similar. C-E: 1H-15N HSQC spectra 
representing NMR titration of the 15N-labeled Pur-alpha I-II with increasing amounts of unlabeled 5’-GCGGA-3’ ssDNA and RNA, 
respectively. Arrows indicate chemical shift pertubations seen upon nucleic acid binding. C: (Left) Overlayed spectra of titration with DNA 
and RNA. The peaks corresponding to the free, DNA-bound (1:1 ratio) and RNA-bound (1:1 ratio) protein states are blue, red and green, 
respectively. (Right) Close-up on the dashed area with the same color code. D: Titration with DNA. (Left) Peaks corresponding to the free 
and DNA-bound (protein:DNA 1:0.5, 1:1, 1:1.5 and 1:5 ratio) protein states are represented in blue, green, red, mauve and orange, 
respectively. (Right) Close-up on the dashed area with the same color code. E: Titration with RNA. (Left) Peaks corresponding to the free 
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and RNA-bound (protein:RNA 1:0.5, 1:1, 1:1.5 and 1:5 ratio) protein states are represented. Color code as in D. (Right) Close-up on the 
dashed area with the same color code. 
 
2.1.4. Crystallization of Pur-α/DNA co-complex 
Selenomethionine (SeMet)-labeled Drosophila Pur-α, comprising Pur-repeat I and II (aa 40-
185), was expressed in E.coli and purified as described in chapter 4.13.2. Crystallization trials 
with Pur-α-DNA co-complexes were set up as described in chapter 4.15.1.  
Rod-shaped crystals of 160 x 20 µm size (Figure 2.4 A) appeared within 4 days at 21°C in 
0.05 M MES; pH 5,6; 8 % PEG400; 0,4 M ammonium sulfate and 1 mM TCEP. 
Crystallization trials with native Pur-α protein and DNA in the same conditions did not result 
in crystals. Alike no protein-RNA crystals grew. 
 
2.1.4.1. Structure determination and refinement 
Synchrotron radiation diffraction data were collected at the ESRF (Grenoble, France). SeMet-
Pur-α:DNA crystals diffracted up to 2.0 Å resolution (Figure 2.4 B) and belonged to 
spacegroup P 21212. Cell constants are a = 81.94, b = 40.19, c = 48.81 Å and angles α = β = γ 
= 90º. A native dataset was recorded at beamline ID 23-2 with a wavelength of 0.8726 Å. A 
Mar/Rayonix 3x3 Mosaic 225 detector was used to collect 180 frames with an oscillation 
range of 2°. The detector distance was set to 265.357 mm (Table 2.1). 
An anomalous dataset was not recorded. 
 
 
Figure 2.4 Pur-α:DNA crystals diffracted up to 2.0 Å. A: Rod-shaped crystals of SeMet-substituted Drosophila Pur-α I-II in complex with 
CGG DNA (7nt). B: Diffraction image of the crystal in A. 
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Data collection Refinement 
X-ray source ID23-2 (ESRF) Resolution (Å) 41.9-2.0 
Space group P21212 No. Reflections 11349 
  Rwork/Rfree 16.3/21.5 
Cell dimension Completeness (%) 99.4 
a, b, c (Å) 81.9, 40.2, 48.8   
α, β, γ (°) 90, 90, 90 No. Atoms 
  Total 1484 
Wavelength (Å) 0.8726 Protein 1207 
Resolution (Å) 50-2.0 DNA 145 
Rmeas 12.5 (79.3) Water 126 
I/σ| 18.85 (2.61)   
Completeness (%) 99.4 (94.3) B-factors 
Redundancy 13.1 (7.6) Protein 24.8 
  DNA 30.4 
  Water 35.2 
    
  R.m.s deviations 
  Bond lengths (Å) 0.008 
  Bond angles (Å) 1.25 
    
  Ramachandran plot (%) 
  Favored 96.03 
  Allowed 3.31 
  Outliers 0.66 
    
  Rotamer outliers (%) 0.76 
Table 2.1 Data collection for the crystal structure of Drosophila Pur-α I-II in complex with DNA 
 
2.1.4.2. Crystal structure of Pur-α/DNA co-complex 
The structure was solved and refined as described in chapter 4.15.1. and Table 2.1. The 
asymmetric unit consists of one Pur-α and one ssDNA molecule. The DNA molecule is 
clamped between the interacting residues of Pur-repeat I and II (Figure 2.5 A).  
Plotting the structure with the programme Nucplot (Figure 2.5 B) revealed the following 
interaction sites: K138 (β-sheet), N140 and R142 (loop region, Pur-repeat II) (Figure 2.5 C), 
Q52, S53 and K54 (loop region, Pur-repeat I) (Figure 2.5 D). Pur-α rather binds to guanine 
bases, but also to one of the cytosines (C5) and the sugar phosphate backbone (Figure 2.5 B). 
Within the crystal lattice the first two DNA bases (G1 and C2) of the 5’-end are base pairing 
with the 5’-end of the symmetry related DNA molecule (Figure 2.5 F and H). The cytosine C5 
in the middle of the DNA strand is twisted and does not stack with the neighboring guanines 
(Figure 2.5 E). Instead F145 (β-sheet) on Pur-repeat II blocks the space for the cytosine C5 
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and undertakes the stacking with the upstream guanine G4 (Figure 2.5 E). This might 
contribute to the stabilization of ssDNA, a known property of Pur-α (Darbinian et al., 2001).  
Pur-α consists of three Pur-repeats that share a moderate sequence identity (~30 %) and adopt 
the same fold (Graebsch et al., 2009 & 2010). Pur-repeat I and II together form the 
DNA/RNA binding domain whereas repeat III functions as a dimerization domain (Graebsch 
et al., 2009). Hence, the DNA binding motifs found on Pur-repeat II can also be found on Pur-
repeat I. The interacting residues K138, N140, R142 and F145 on Pur-repeat II have their 
counterpart on Pur-repeat I in position K61 (β-sheet), N63, R65 (loop region) (KNR I) and 
F68 (β-sheet) (F I). Except for the K61 none of the other residues on Pur-repeat I have been 
found to interact with the DNA in the crystal structure. Additional binding sites on Pur-
repeat I on the symmetry related protein molecule interact with the 3’-end of the DNA (Figure 
2.5 F and G): Y57, D59, K61 and K70 and R80 (β-sheet). This interface might therefore 
represent a second potential DNA/RNA binding site, which is asymmetric to the binding site 
on Pur-repeat II.  
Otherwise, crystallographic packing forces might have prevented DNA binding to the 
identical motif (KNR) on Pur-repeat I and therefore shifted the binding to a similar motif 
further downstream composed of the same residues (lysine, arginine) and a tyrosine for 
guanine base stacking.
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Figure 2.5 Crystal structure of Pur-α I-II in complex with the 5’-GCGGCGG-3’ ssDNA. A: Ribbon backbone model of the DNA/RNA-
binding domain formed by PUR repeat I (green) and II (blue) in complex with DNA (cyan), represented in sticks. Important protein residues 
involved in DNA interactions are depicted in red sticks. B: Schematic representation of Pur-α interaction with DNA. Both PUR repeats are 
involved in DNA binding. Pur-α rather binds to guanine bases, but also to one of the cytosines and the sugar phosphate backbone. Residues 
of the symmetry related protein molecule that interact with DNA are depicted in brown. C-E: Detail of the protein-DNA interaction sites. E: 
Phenylalanine 145 stacks with the guanine base G4 and blocks the space for the following cytosine C5. F: Within the crystal lattice the 5’-
end of the DNA (cyan) anneals with the 5’-end of the symmetry related DNA molecule (red). The 3’-end of the DNA (cyan) is bound by 
several residues (red) of repeat I of the symmetry related protein molecule (gray). G: Detail of the DNA interaction sites with residues (red) 
of repeat I of the symmetry related protein (grey). H: Detail of the G1 and C2 (cyan) base pairing with the symmetry related DNA molecule 
(red). 
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2.1.4.3. Structural comparison of Pur-α co-complex and apo-structure 
In order to verify if Pur-α undergoes conformational changes upon DNA binding a structural 
comparison of the Pur-α I-II apo-structure (PDB ID 3K44) and the structure of the protein-
DNA co-complex was performed using the SSM (secondary-structure matching) superpose 
algorithm (Krissinel and Henrick, 2004) of the program COOT. Alignment of these two 
structures (Figure 2.6 A and B) did not show major conformational differences of free and 
DNA-bound protein. The root-mean-square deviation (RMSD) of atomic positions obtained a 
score of 1.14 Å. Excluding the flexible loop region (aa 107-120) from the calculations, the 
RMSD even improved to a score of 0.83 Å and confirmed that DNA binding does not induce 
a conformational change of Pur-α. 
 
 
Figure 2.6 Pur-α does not undergo conformational 
changes upon DNA binding. A and B: Structure 
alignment of D. melanogaster Pur-α I-II apo-
structure and in complex with ssDNA (A, DNA 
displayed; B, DNA not diplayed). Root-mean-square 
deviation (RMSD) is indicated in the figures. 
 
 
 
2.1.4.4. Sequence alignment of Pur-α from different species 
Pur-α is a highly conserved protein from bacteria to mammals. An amino acid sequence 
alignment of Pur-α from different species (Drosophila melanogaster, Homo sapiens, Danio 
reiro and Caenorhabditis elegans) was done to see if the interaction sites seen in the crystal 
structure are conserved residues (Figure 2.7). Indeed, Q52, S53 and K54, which form one of 
the two main interaction sites on Pur-repeat I (QSK I) are highly conserved. The opposing 
binding site on Pur-repeat II composed of K138, N140 and R142 (KNR II) is also highly 
conserved. The DNA twisting seen in the crystal structure is a special feature of Pur-α’s 
interaction with DNA. Flipping out of the cytosine C5 is caused by stacking of F145 on Pur-
repeat II (F II) with the guanine G4 base and thereby blocking the space for the cytosine. The 
sequence alignment shows that also the F145 (F II) is a highly conserved residue and might 
therefore be of functional importance. The high conservation of the interacting residues 
presents the basis for further DNA/RNA interaction studies with Pur-α mutants. The binding 
motif KNR and F on Pur-repeat II can also be found on Pur-repeat I (KNR I and F I) and 
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share a high conservation score. Hence, mutations of these residues were also considered for 
functional assays with Pur-α. 
 
 
Figure 2.7 Amino acid sequence alignment of Pur-α 
from different species. D.m., Drosophila melanogaster; 
H.s., Homo sapiens; D.r., Danio rerio; C.e., 
Caenorhabditis elegans. Color-coding from blue to red 
reflects the range of sequence conservation from 0-
100 %. Asterisk indicates positions, which have a single, 
fully conserved residue. Colon indicates conservation 
between groups of strongly similar properties. Period 
indicates conservation between groups of weakly similar 
properties. Secondary structure assignment is based on 
the crystal structure of Pur-α I-II. Secondary structure 
prediction of Pur-repeat III is based on sequence 
alignment with Pur-repeats I and II. Red boxes indicate 
mutation sites for DNA/RNA interaction studies. 
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2.1.5. EMSA with mutant Pur-α and DNA/RNA 
To verify the interaction sites seen in the crystal structure and to test if there is a second 
binding site on Pur-repeat I, several point mutations have been introduced and their effect on 
DNA/RNA binding has been analyzed in radioactive EMSA experiments. Residues of the 
DNA binding site on Pur-repeat I and II and the potential second binding site on Pur-repeat I 
have been chosen for site-directed mutagenesis. The respective residues have been replaced 
by alanine: K61, N63, R65 (KNR I, triple mutant), K138, N140, R142 (KNR II, triple mutant), 
F68 (F I), F145 (F II). For the triple mutant Q52, S53, K54 (QSK I) residues were replaced by 
glycine, since the alanine-mutant versions of the protein tended to aggregate during 
purification. Likewise, the residues of the mutant Q52, S53, K54, K138, N140, R142 (QSK I 
- KNR II) were replaced by glycine (Q52, S53, K54) and by alanine (K138, N140, R142), 
respectively. The mutant proteins were expressed and purified as described in chapter 4.13.1. 
and 4.13.2. EMSA experiments were performed with CGG-repeat and MF0677 DNA/RNA 
oligomers (24 nt). All Pur-α I-II mutants show decreased binding to both DNA/RNA motifs 
(Figure 2.8 A-H) and, as in chapter 2.1.2, showed similar reductions in affinity for DNA and 
RNA oligomers with identical sequences. However, for the F II mutant binding to RNA 
seems to be only slightly decreased (Figure 2.8 E and F). Circular dichroism (CD) 
spectroscopy showed that all generated Pur-α I-II mutants were correctly folded (Figure 2.9) 
and verified the composition of α-helix and β-sheet structures. 
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Figure 2.8 Drosophila Pur-α I-II mutants show decreased binding affinity to DNA and RNA. A, C, E, G: EMSA with wild type and 
mutant Pur-α I-II and MF067 ssDNA (left) and RNA (right), respectively. B, D, F, H: EMSA with wild type and mutant Pur-α I-II and 
CGG-repeat ssDNA (left) and RNA (right). 
 
 
 
Figure 2.9 Folding of the wild type Pur-α I-II and the mutants are 
equal. Overlay of CD spectra of Drosophila Pur-α I-II (depicted in 
blue) and mutants (each depicted in a different color). 
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2.1.6. EMSA with Pur-α III and DNA/RNA 
Previously it has been shown that the third Pur-repeat hardly contributes to DNA/RNA 
binding, but that it is necessary for Pur-α dimerization (Graebsch et al., 2009). Here 
DNA/RNA binding of Pur-α III alone was analyzed in radioactive EMSA experiments with 
CGG-repeat and MF0677 DNA/RNA oligomers (24 nt). Neither the CGG-repeat sequence 
nor the physiological Pur-α target sequence MF0677 bound to Pur-α III as strong as to Pur-α 
I-II (Figure 2.10 A and B). The main DNA/RNA interaction might therefore occur via the 
first two Pur-repeats. 
 
 
Figure 2.10 Drosophila Pur-α III shows only weak binding affinity to 
DNA and RNA. A: EMSA with wild type Pur-α I-II and Pur-α III  and 
MF067 ssDNA (left) and RNA (right), respectively. B: EMSA with wild 
type Pur-α I-II and Pur-α III  and CGG-repeat ssDNA (left) and RNA (right), 
respectively. 
 
 
 
 
 
 
2.1.7. EMSA with Pur-α I-II and FTD/ALS-related repeat RNA 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease, which causes death of 
motor neurons (reviewed in Robberecht and Philips, 2013). 15% of ALS patients also suffer 
from frontotemporal lobar degeneration (FTLD) (Ringholz et al., 2005), which is the second 
most common dementia after Alzheimer’s disease (Harvey et al., 2003; Van Langenhove et 
al., 2012). Similar to the Fragile X-associated tremor/ataxia syndrome (FXTAS) the major 
neuropathological feature of ALS/FTLD are neuronal, proteinaceous inclusions. Inclusions in 
ALS/FTLD are caused by hexanucleotide (G4C2) expansion mutations in the non-coding 
region of C9orf72 locus, which accounts for up to 25% of FTD and 40 % of familiar ALS 
(Stepto et al., 2014). The pathogenic function of the repeat-expanded RNA arises from the 
formation of RNA foci containing hairpin structures and G-quadruplexes. These RNA 
structures cause sequestration of RNA binding proteins and, alike in FXTAS, Pur-α has been 
found to be part of FTD/ALS inclusions. In order to validate if Pur-α can bind to the ALS-
related RNA radioactive EMSA experiments with (G4C2)4 RNA oligomers have been 
performed. Pur-α shows a similar affinity to G4C2-repeat RNA like to CGG-repeat RNA 
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(estimated KD ~2 µM). Mutation in the DNA/RNA binding site (KNR II) decreases the 
affinity and leads to the assumption that both RNA sequences are bound in a similar way 
(Figure 2.11). 
 
 
Figure 2.11 Drosophila Pur-α I-II KNR II mutant shows decreased binding affinity to ALS-
related repeat-RNA. EMSA with wild type Pur-α I-II and KNR II mutant and (G4C2)4 RNA. 
 
 
 
 
2.1.8. Unwinding assay 
Pur-α is able to unwind dsDNA containing a GGN motif in an ATP-independent manner 
(Darbinian et al., 2001; Wortman et al., 2005). For this the protein contacts the purine-rich 
strand and displaces the pyrimidine-rich strand (Wortman et al., 2005). It has been postulated 
that Pur-α, being a transcription activator, binds to promoter regions, displaces the two DNA 
strands so other proteins can bind and activate transcription (Darbinian et al., 2001). 
The crystal structure of the Pur-α-DNA co-complex shows that the normal base stacking of 
the ssDNA is disrupted and that the cytosine C5 is flipped out because the F145 takes over the 
stacking with the upstream guanine G4 (chapter 2.1.4.2). Additionally, the 5’-end and the 3’-
end of the ssDNA are bound by two Pur-α molecules within the crystal lattice, which enforces 
the unusual twisting. This particular feature of DNA binding might explain how DNA double-
strand separation could occur. To test if the binding mode seen in the crystal structure is 
essential for the strand displacement of dsDNA unwinding assays with mutant Pur-α and 
dsDNA substrates were performed. Radiolabeled ssDNA oligomer containing a GGN motif 
was annealed to an ssDNA plasmid. The resulting partly double-stranded substrate was 
incubated with Pur-α wild type and mutants and strand separation has been monitored on 
polyacrylamide gels. When both binding sites on Pur-repeat I and II were mutated (QSK I – 
KNR II) unwinding was not possible anymore (Figure 2.12 A), most likely because DNA 
binding was impaired as seen in EMSA experiments (chapter 2.1.5, Figure 2.8 C). An 
unwinding assay with the F145 (F II) mutant confirmed that flipping out of one base is 
essential for unwinding and that F145 plays an important role in this context. Mutating only 
the F145 already abolished the unwinding activity (Figure 2.12 B), whereas all other 
mutations showed only decreased unwinding (Figure 2.12 C-F). Results of all binding and 
unwinding experiments for all Pur-α derivatives are summarized in Figure 2.12 G. 
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Figure 2.12 Mutations in Pur-α I-II decrease dsDNA unwinding ability. Unwinding assay with different D. melanogaster Pur-α I-II 
mutants and Pur-α III. Protein was titrated to a partly dsDNA substrate containing a GGN motif. Pur-alpha I-II is able to separate the DNA 
strands, whereas mutations in both repeats (A) and the mutation of the phenylalanine 145 in repeat II (B) abolish the unwinding ability. 
Mutations in repeat II only (C) or in the identical motif of repeat I (D) decrease the unwinding ability. (E) Pur-alpha III shows only weak 
unwinding activity. Decreased unwinding also occurs upon mutation of phenylalanine 68 in repeat I (F). The table (G) summarizes the 
results of all EMSA and unwinding experiments of all Pur-α derivatives and mutants. 
 
 
2.1.9. Small angle X-ray scattering (SAXS) 
Pur-repeat I and II share a high sequence and structure similarity and together form the 
DNA/RNA binding domain. The crystal structure of Pur-α I-II in complex with DNA shows 
that there are two binding sites and demonstrates that one DNA/RNA binding domain binds 
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two molecules of nucleic acid. Due to crystal packing only one molecule of DNA might be 
able to bind to each DNA/RNA binding domain. Since stoichiometry of the Pur-α/DNA co-
complex could not be determined in NMR titration experiments, small angle x-ray scattering 
(SAXS) was applied. Therefore, several measurements were done with the MF0677 (24 nt) 
and CGG (7 nt) ssDNA and either Pur-α I-II or Pur-α I-III, a dimer in solution. SAXS 
measurements with the MF0677 oligonucleotide failed due to precipitation and addition of 
CGG ssDNA to Pur-α I-II or Pur-α I-III at a 1:1 ratio resulted in formation of polydisperse 
oligomers, therefore these data were not further evaluated. Addition of a two-fold excess of 
DNA caused precipitation and therefore samples could not be measured. Precipitation was 
probably caused by the relatively high protein concentration (50 µM) needed for signal 
detection. Calculation of a stoichiometric ratio for a Pur-α/DNA co-complex was therefore 
impossible. To prevent oligomerisation the ionic strength of the buffer was increased from 
250 mM to 500 mM and 1 M NaCl. This prevented on the one hand uncontrolled 
oligomerisation, but on the other hand hindered dimerization of Pur-α I-III so that the results 
obtained from SAXS measurements were not reliable anymore. 
 
 
2.1.10. Dot blot assay 
Since the stoichiometry of the Pur-α/DNA co-complex could neither be determined in NMR 
titration experiments nor in SAXS measurements a different technique was used that does not 
need a high protein concentration and therefore avoids oligomerisation and aggregation. 
Though, to determine the complex stoichiometry the nucleic acid concentration needs to be 
above the KD to ensure that all protein is bound. The estimated KD for Pur-α I-II and MF0677 
(24 nt) ssDNA was approximately 150 nM (Figure 2.2 A). In a so-called dot blot assay Pur-α 
I-II was titrated to a constant amount (1 µM) of radiolabeled MF0677 (24 nt) ssDNA and 
blotted onto a nitrocellulose membrane (Figure 2.13 A). Only protein or protein/DNA 
complexes can bind to the nitrocellulose membrane whereby unbound oligomers are washed 
away. The radioactive signal on the membrane was measured with a phosphor imager system 
as an indicator for radiolabeled DNA bound to Pur-α. By plotting the signal intensity against 
the protein concentration saturation curves were obtained. In the case of a 1:1 ratio 
(protein:DNA), saturation would be reached at a protein concentration of 1 µM. In the case of 
a 1:2 ratio (protein:DNA) saturation would already occur at 0.5 µM. As shown in Figure 2.13 
A (from left to right), in three independent experiments saturation was already reached at 
protein concentrations of 0.45, 0.64 and 0.64 µM, respectively. Taken together, saturation 
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occurs at a mean value of 0.58 ± 0.1 µM of Pur-α (Figure 2.13 B), which indicates a 
stoichiometric ratio of 1:2 (protein:DNA). Thus, in solution Pur-α I-II can bind two molecules 
of ssDNA. This result is consistent with the two binding sites observed in the crystal structure 
(Figure 2.5). 
 
 
Figure 2.13 One Pur-α I-II molecule can bind two ssDNA molecules. A: (From left to right) Three independent filter binding assays with 
D. melanogaster Pur-α I-II and MF0677 ssDNA. Nitrocellulose filters (top) show the titration of Pur-α I-II (0-1.5 µM) to a constant amount 
of ssDNA (1 µM). The measured intensities from the filters were quantitatively analyzed. The graphs (bottom) show when saturation is 
reached. B: The mean protein concentration at which saturation is reached was calculated from all three assays. Results indicate that one Pur-
α I-II molecule binds two ssDNA molecules. 
 
 
2.1.11. DNase I footprint 
Pur-α is a DNA/RNA binding protein that binds to purine-rich elements, which can be found 
at promoter regions (Haas et al., 1995) and origins of replication (Darbinian et al., 2001, 
Gallia et al., 2000). One known promoter region where Pur-α binds to is the MF0677 
sequence upstream of the c-myc gene (Haas et al., 1995). To investigate Pur-α’s binding mode 
to its physiological target, DNaseI footprint assays were performed using the DNA sequence 
upstream of the c-myc gene (myc-MF0677). 
First, radioactive EMSA experiments with Pur-α and the physiological target sequence were 
performed in order to estimate the required protein concentration for footprint assays. 
Estimated from the remaining band of free DNA seen in the gel, Drosophila Pur-α I-II bound 
to myc-MF0677 ssDNA (150 nt) with a KD of approximately 5 µM (Figure 2.14A). Human 
Pur-α I-III bound to the myc-MF0677 dsDNA (160 bp) substrate with a similar affinity 
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(Figure 2.14 B). The range of protein concentration chosen for footprint assays was therefore 
2-10 µM.  
DNase I footprints were carried out as described in chapter 4.16.8. Pur-α was incubated with 
radiolabeled myc-MF0677 DNA previous to DNase I digestion. Sites where Pur-α binds to 
should be protected from DNase I cleavage and therefore appear in the gel as “missing bands” 
when compared to the digested DNA not incubated with Pur-α (control). Different amounts of 
Pur-α and DNase I were applied. The sequencing reaction loaded on the same gel allows for 
the determination of the nucleotide sequence where Pur-α binds.  
The footprint assay with Drosophila Pur-α I-II and myc-MF0677 ssDNA (150 nt) showed a 
protected site that is located at the 3’-end of the MF0677 subfragment used in EMSA 
experiments (chapter 2.1.2) (Figure 2.15 A). Surprisingly the protected region did not include 
a GGN motif. To test if Pur-α really binds to the identified sequence, EMSA experiments with 
DNA oligomers of the protected sequence and the unprotected 5’-end of the MF0677 
sequence were performed. The EMSA assays showed that Pur-α binds with high affinity to 
the 5’-end of the MF0677 oligomer that contains a GGN motif and was not protected in the 
DNase I footprint (Figure 2.16 B), but only with a very low affinity to the 3’-end of the 
MF0677 oligomer that does not contain a GGN motif, but was protected in the footprint 
(Figure 2.16 A). Results of this footprint assay were therefore unreliable and could not be 
reproduced either. 
Also footprint assays with dsDNA (myc-MF0677, 160 bp) and human Pur-α containing all 
three Pur-repeats did not give any conclusion about Pur-α’s binding mode to its physiological 
target, since no protected sites were detectable (Figure 2.15 B). 
 
 
Figure 2.14 Pur-α binds to the MF0677 ss/dsDNA used in DNaseI footprints. 
A: EMSA with Drosophila Pur-α I-II and radiolabeled MF0677 ssDNA 8150 nt). 
B: EMSA with human Pur-α I-III and radiolabeled MF0677 dsDNA (160 bp). 
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Figure 2.15 DNase I footprint assays. A: ssDNA myc-MF0677 (150 nt) incubated with D. melanogaster Pur-α I-II was digested with 
DNase I. B: DsDNA myc-Mf0677 (160 nt) incubated with human Pur-α I-III was digested with DNase I. Digestion of ssDNA and dsDNA, 
respectively, without protein was used as a control. Protein concentrations and DNase I concentrations were varied as depicted in the figure. 
Probes were run on a polyacrylamide gel. For sequence determination a sequencing reaction was also loaded on the gel. The region of the 
MF0677 DNA (24 nt) sequence used in EMSA experiments and filter-binding assays is indicated. Protected sites are depicted with a red dash. 
For the dsDNA footprint no protected sites were detectable. 
 
 
Figure 2.16 Pur-α does not bind to the sequence, which is 
protected in DNase I footprint assays, but to the GGN motif of the 
MF0677 sequence, which is not protected in the footprint assay. 
EMSA with Drosophila Pur-α I-II and fluorescently labeled ssDNA. 
A: EMSA with the “protected” DNA sequecence. B: EMSA with 
“unprotected” GGN motif of the MF0677 sequence. 
 
 
 
2.2. Cell culture studies 
2.2.1. Cellular function of Pur-α 
Many reports suggest a role of Pur-α in activation of transcription and replication. It has been 
shown that Pur-α possesses dsDNA destabilizing activity (this study, Darbinian et al., 2001; 
Wortman et al., 2005) and is involved in transcription of several neuronal genes including the 
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myeline basic protein gene that is important for myelination of nerves in the central nervous 
system (CNS) (Darbinian et al., 2001; Haas et al., 1995). Mice with disruption in the Pur-α 
gene in both alleles (PURA -/-) appear normal at birth, but after 2 weeks they develop 
neurological problems and die after 4 weeks (Khalili et al., 2003). To gain information about 
Pur-α’s role in replication and transcription and to better understand why Pur-α knockout 
mice die after birth, Chip-Seq experiments with human Pur-α were planned. 
 
2.2.1.1. CHIP-Seq 
CHIP-Seq is an in vivo method that combines chromatin immunoprecipitation (CHIP) with 
DNA sequencing (Seq). This method uses antibodies to capture proteins that are either 
directly bound to DNA or indirectly through protein-protein interaction. Thus, binding sites of 
DNA-associated proteins can be identified. Chip-Seq assays could thereby answer the 
question, which genes become activated by Pur-α binding, if they share a consensus sequence, 
and if they can be classified into functional groups.  
 
2.2.1.2. Antibody test against human Pur-α 
For CHIP an antibody is needed that specifically targets the protein of interest. Therefore, one 
commercial and two in-house-produced antibodies against human Pur-α were tested in 
western blot assays for Pur-α specificity. 20 µg of total protein from HeLa cells and 10 µg of 
recombinant Drosophila Pur-α I-II protein were loaded on SDS PAGE and blotted onto a 
nitrocellulose membrane. The blot was then incubated with the primary anti-Pur-α antibodies 
to detect human Pur-α (~ 37 kDa) and the primary anti-α-actin (~ 43 kDa) antibody to detect 
α-actin as a loading control. After incubation with the corresponding HRP-conjugated 
secondary antibody, protein signals were detected using the ECL substrate and light-sensitive 
films. None of the self-produced Pur-α antibodies showed specific binding to human Pur-α 
from HeLa cells (Figure 2.17 A, lane 2 and 3), but detected the recombinantly expressed 
Drosophila protein (Figure 2.17 A, lane 4). Likewise, the commercial antibody did not show 
specific binding to human Pur-α from HeLa cells (Figure 2. B, lane 2), but detected the 
recombinant Drosophila protein (Figure 2.17 B, lane 3). Specific detection of α-actin as a 
loading control worked nicely (Figure 2.17 A and B, lane 1). As a conclusion, the tested 
antibodies were not suitable for immunoprecipitation (IP) experiments because of their 
unspecific binding. 
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Figure 2.17 Unspecific binding of human Pur-α (hPur-
α) antibody. A: Tissue culture supernatants (TCS) of 2 
different cell clones were tested for human Pur-α (32 kDa) 
detection in western blot experiments with HeLa protein 
lysate. None of the TCS (lane 2 and 3) specifically detected 
human Pur-α. Lane 4 was loaded with recombinant D. 
melanogaster Pur-α I-II as an indicator for unspecific 
protein binding. Detection of α-actin (43 kDa) served as a 
loading control (lane 1). B: Similar to A, using a 
commercial human Pur-α antibody (lane 2 and 3). No 
specific detection of human Pur-α. Lane 3 was loaded with 
recombinant D. melanogaster Pur-α I-II as an indicator for 
unspecific protein binding. Detection of α-actin (43 kDa) 
served as a loading control (lane 1). 
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2.2.1.3. Generation of vectors for expression tagged human Pur-α 
Since the tested antibodies against human Pur-α did not show specificity and commercial 
antibodies might additionally cross-react with other proteins of the Pur-family, tagging Pur-α 
would enable IPs with a more specific antibody against the tag. Therefore, I used a BAC 
(bacterial artificial chromosome) clone that contains the genomic human Pur-α sequence, 
including upstream and downstream regulatory regions (Figure 2.18 A). Pur-α was either N-
terminally or C-terminally tagged (Figure 2.18 B and C, top) via homologous recombination 
using an eGFP-tagging cassette containing a geneticin-neomycin resistance for clone selection. 
Successful tagging was verified by amplification of eGFP or eGFP-tagged human Pur-α via 
PCR (Figure 2.18 B and C, bottom). Because the BAC constructs contain the genomic 
promoter and regulatory sequences, tagged-Pur-α protein expression underlies the same 
regulation as the protein expression of the endogenous Pur-α gene and does not have to be 
induced artificially. Eventually IPs can be carried out with an antibody against eGFP. 
 
 
Figure 2.18 BAC constructs of human Pur-α. A: Linear scheme of the unmodified BAC containing the human Pur-α DNA sequence and 
the regulatory regions up- and downstream of the gene. B: (Top) Scheme of N- (left) and C-terminally (right) tagged human Pur-α. The tag 
consists of eGFP, Prescission protease cleavage site (P), S-peptide (S) and TEV cleavage site (T). Positive BAC clones were verified by 
amplification of the eGFP sequence (B, bottom, lane 1) with primers that bind within the eGFP sequence or eGFP tagged human Pur-α (C, 
bottom, lane 3) with primes that bind within the human Pur-α gene and the BAC backbone. As a control for N-terminally tagged human Pur-
α, eGFP was amplified from the N-terminal tagging cassette (B, bottom, lane 2). As a control for C-terminally tagged human Pur-α PCR was 
performed with the unmodified BAC as template (C, bottom, lane 4). M, Molecular weight marker. 
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2.2.1.4. BAC transfection and cell selection 
The BAC constructs carrying either N- (Figure 2.18 B, top) or C-terminally (Figure 2.18 C, 
top) tagged human Pur-α were transfected into HeLa cells. Clones carrying tagged human 
Pur-α constructs were selected for antibiotic resistance with increasing geneticin (G418) 
concentrations in order to establish a stable cell line. After 4 weeks of G418 selection all cells 
transfected with the untagged BAC, lacking the antibiotic resistance, were dead (Figure 
2.19 C). However, three clones containing the N-terminally and three clones containing the C-
terminally tagged human Pur-α BAC construct survived and grew to bigger colonies within a 
few weeks (Figure 2.19 A and B). Eventually, from the C-terminally tagged BAC colonies 
only one persisted. 
 
 
 
Figure 2.19 HeLa cell colonies carrying BAC constructs with eGFP tagged human Pur-α after 4 weeks of antibiotic selection. A: 
(From left to right) three different cell colonies holding the BAC construct with N-terminally tagged human Pur-α. B: (From left to right) 
three different cell colonies holding the BAC construct with C-terminally tagged human Pur-α. C: HeLa cells transfected with unmodified 
BAC died during antibiotic selection. 
 
2.2.1.5. Validation of GFP-Pur-α expression 
Geneticin resistant colonies carrying either N- or C-terminally eGFP-tagged human Pur-α 
BAC constructs were further amplified and tested for eGFP expression in western blot assays 
as described in chapter 4.18. Cells of one clone that contains C-terminally tagged Pur-α, cells 
of three different clones with N-terminally tagged Pur-α and untransfected HeLa cells were 
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harvested. Of each cell line 20 µg of total protein per lane were run on SDS PAGE and blotted 
onto a nitrocellulose membrane. The blot was then incubated with primary anti-GFP antibody 
to detect eGFP-tagged Pur-α (~ 62 kDa) and primary anti-α-actin (~ 43 kDa) antibody to 
detect α-actin as a loading control. After incubation with the corresponding HRP-conjugated 
secondary antibody, protein signals were detected using the ECL substrate and light-sensitive 
films. The blot did not show any specific protein band for eGFP-tagged Pur-α (~ 62 kDa), 
neither for the N-terminally, nor for the C-terminally tagged constructs (Figure 2.20). The 
lane loaded with untransfected HeLa protein lysate showed the same unspecific band pattern 
like the other cell lines. Only α-actin gave a strong and specific protein signal and confirmed 
that the same amount of total protein was loaded for each cell line (Figure 2.20).  
 
 
Figure 2.20 Expression test of GFP-tagged hPur-α from HeLa protein 
lysate. Western blot of HeLa cells stably transfected with BAC constructs 
containing N- or C-terminally eGFP-tagged human Pur-α. No GFP signal was 
detected for the N-terminally tagged (N-term, lane 1-3) or the C-terminally 
tagged human Pur-α (C-term, lane 1). Protein lysate of untransfected HeLa 
cells were loaded as a control (HeLa). 
 
 
 
As the transfected HeLa cells are resistant to geneticin, but do not show expression of eGFP-
tagged Pur-α in western blot assays, fluorescence microscopy was used as an alternative 
technique to detect GFP signal. However none of the stable cell lines gave a fluorescence 
signal. This can be explained by either silenced eGFP-Pur-α expression or exclusion of the 
eGFP-Pur-α gene from the genome during cell selection, while maintaining the antibiotic 
resistance. 
 
2.2.2. Pur-α and FXTAS 
It has been implied that Pur-α is involved in the pathomechanism of the fragile X-associated 
tremor/ataxia syndrome (FXTAS) (Jin et al., 2007). FXTAS is caused by premutation 
expansions (55-200 CGG repeats) in the 5’UTR in the fragile X mental retardation 1 (fmr1) 
gene (Oostra Willemsen 2009), which lead to intranuclear and astrocytic inclusions 
throughout the brain (Greco et al., 2006; Iwahashi et al., 2006). Amongst other proteins, Pur-α 
has been found to be part of these inclusions together with the fmr1 mRNA (Iwahashi et al., 
2006; Jin et al., 2007). Since CGG repeats are known binding sites for Pur-α (Jin et al., 2003), 
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it has been suggested that Pur-α binds to the CGG-repeat RNA leading to sequestration of 
Pur-α and other CGG-binding proteins in the pathogenesis of this disease. CGG-repeat 
induced intranuclear inclusions have also been found in cell and Drosophila models (Jin et al., 
2007; Sofola et al., 2007). 
Therefore, it was planned to further investigate Pur-α’s role in FXTAS by performing cell-
culture studies with a mammalian cell line stably expressing CGG-repeat RNA.  
 
2.2.2.1. CGG-repeat RNA expression in COS7 cells 
Expression of CGG-repeat RNA (with 60 or more repeats) in COS7 cells has been shown to 
result in formation of nuclear inclusions (Sellier et al., 2010). These inclusions can be purified 
from nuclear extracts. I planned to perform in vivo cross-linking of the fmr1 5’UTR, followed 
by either 30 (normal repeat length) or 95 (FXTAS-related repeat length) CGG repeats, with 
its bound proteins. After isolation of the cross-linked RNA-protein complexes and subsequent 
mass spectrometry analysis, I wanted to determine the proteins that directly bind to the CGG-
repeat RNA, identify potential interaction partners of Pur-α and compare the results found for 
the normal and disease-related CGG-repeat RNA. 
 
2.2.2.2. Generation of vectors for CGG-repeat RNA expression 
The fmr1 5’UTR containing either 30 or 95 CGG repeats was cloned into a mammalian 
expression vector (pRTS-1) (Figure 2.21 A, left), which contains a GFP reporter and 
hygromycin resistance. The CGG-repeat RNA and the GFP reporter are both under the 
control of a bi-directional CMV (cytomegalovirus) promoter. Expression is inducible by 
doxycycline (TET-ON advanced system).  
Furthermore, the CGG-repeat RNA has been cloned into another mammalian expression 
vector (pRTR) that additionally contains a CD2 (cluster of differentiation 2) gene expressed 
from the SV40 (simian virus 40) promoter (Figure 2.21 B, left). The CD2 gene encodes for a 
cell adhesion protein on the cell surface that enables cell selection via magnetic beads shortly 
after transfection.  
For RNA-isolation, the CGG-repeat RNA was tagged using a two-component system 
consisting of a bacteriophage coat protein PP7 (serine/threonine protein phosphatase 7, PP7-
CP) and 24 RNA stem-loop structures (24x PP7-SL), which are recognized by the PP7-CP. 
The PP7-CP was cloned into the pRTS-1 and the pRTR vector as a fusion protein at the N-
terminus of eGFP. The 24x PP7-SL were cloned upstream of the CGG-repeat RNA (Figure 
2.21 A, right). Induction with doxycycline leads to simultaneous expression of PP7-CP fused 
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to eGFP and CGG-repeat RNA fused to PP7-SL. The PP7-CP can recognize and bind to the 
PP7-SL and via immunoprecipitation (IP) with an antibody against eGFP the repeat RNA can 
be isolated.  
These four vector constructs (pRTS-1: 30 and 95 CGG repeats, pRTR: 30 and 95 CGG 
repeats) were generated to obtain a stable cell line with strong eGFP and CGG-repeat RNA 
expression, respectively. 
 
 
Figure 2.21 Vector design for CGG-repeat RNA 
expression in COS7 and HeLa cells. A: Scheme of the 
initial pRTS-1 vector (left) and the self-constructed pRTS-
1-PP7 FMR1 5’UTR (CGG)n vector (right). Both vectors 
contain a bidirectional, inducible CMV promoter (blue), 
the gene for eGFP (green) and hygromycin resistance (red). 
The FMR1 5’ UTR followed by either 30 or 95 CGG 
repeats was introduced into the pRTS-1 vector. For tagging 
the CGG-repeat RNA 24 PP7 stem loops were fused 
upstream of the FMR1 5’UTR. The eGFP gene was N-
terminally fused to the PP7 coat protein, which recognizes 
and binds to the PP7 stem loop structures of the CGG-
repeat RNA. B: Scheme of the initial pRTR vector (left) 
and the self-constructed pRTR-PP7 FMR1 5’UTR (CGG)n 
vector (right). Both vectors contain a bidirectional, 
inducible CMV promoter (blue), the gene for eGFP (green) 
and puromycin resistance (purple). As in A the FMR1 5’ 
UTR followed by either 30 or 95 CGG repeats was 
introduced into the pRTR vector, likewise the PP7 tagging 
elements. Additionally, the pRTR vector contains a CD2 
gene (orange) that encodes for a cell adhesion protein on 
the cell surface to enable cell selection via magnetic beads shortly after transfection. 
 
2.2.2.3. Test transfection of initial vectors 
As a preliminary test, the initial vectors pRTS-1 and pRTR (Figure 2.21 A and B, left) were 
transiently transfected into COS7 cells. Twenty-four hours after doxycycline induction, 
expression of the GFP reporter was visualized by fluorescence microscopy. Cells containing 
the pRTS-1 plasmid gave a strong GFP signal compared to cells that were only treated with 
transfection reagent (control) (Figure 2.22 A). Hence, transfection efficiency was reasonable 
and induction with doxycycline worked well. 
Cells containing the pRTR plasmid also gave a strong GFP signal compared to the control, 
but less strong than the pRTS-1-transfected cells. Transfection was less efficient than for the 
pRTS-1 construct (Figure 2.22 B). 
Results 
 47 
 
 
 
 
Figure 2.22 Test expression of initial vectors in COS7 cells. The initial vectors pRTS-1 (A) and pRTR (B) were transiently transfected 
into COS7 cells (top). After induction with doxycycline eGFP expression was analyzed with a fluorescence microscope. The images of phase 
contrast and GFP channel were overlayed. The red box indicates the region, which is shown as zoom in. Untransfected cells, which have 
been treated only with transfection reagent, were used as control (bottom). 
 
2.2.2.4. Transient transfection and induction of CGG-repeat RNA 
Next, COS7 cells were transiently transfected with the pRTS-1 vector containing only the 
untagged CGG-repeat RNA carrying either 30 or 95 CGG repeats and the GFP reporter, both 
under the control of the CMV promoter. After doxycycline induction, GFP fluorescence was 
detected by fluorescence microscopy. A strong GFP signal was detectable for both RNA 
constructs (30 and 95 CGG repeats), compared to the control (Figure 2.23). However, a very 
small amount of cells showed GFP expression compared to the cells transfected with the 
initial pRTS-1 vector (compare Figure 2.22 A). Transfection efficiency of the CGG-repeat 
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RNA constructs was much lower. Additionally, cells transfected with an RNA of 95 CGG 
repeats were more prone to die upon transfection than cells transfected with 30 CGG-repeat 
RNA. 
Cells were then selected for hygromycin resistance for several weeks in order to obtain a cell 
line stably expressing the CGG-repeat RNA and the eGFP reporter. However, GFP 
fluorescent cells could not be accumulated during antibiotic selection. Although all cells were 
hygromycin resistant, only a small portion gave a fluorescence signal. Since antibiotic 
selection seems to be insufficient for generating a stable cell line, selection via magnetic 
beads coupled to an antibody against the cell-surface protein CD2 could increase the number 
of cells expressing the transfected construct. Hence, for further CGG-repeat RNA constructs, 
the pRTR vector, containing the CD2 gene for magnetic bead cell selection, was used. 
 
 
Figure 2.23 Co-expression of eGFP and CGG-repeat RNA in COS7 cells. The pRTS-1 vector containing the CGG-repeat RNA with 
either 30 (top) or 95 CGG (middle) repeats were transiently transfected into COS7 cells. After induction with doxycycline eGFP signal was 
analyzed with a fluorescence microscope as indicator for successful transfection and CGG-repeat RNA expression. The images of phase 
contrast and GFP channel were overlayed. The red box indicates the region, which is shown as zoom in. Untransfected cells, which have 
been treated only with transfection reagent, were used as control (bottom). Transfection efficiency was decreased compared to the 
transfection with the initial pRTS-1 vector without CGG-repeat RNA. 
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2.2.2.5. Transient transfection and induction of PP7-tagged CGG-repeat 
RNA 
The pRTR vector containing tagged CGG-repeat RNA and PP7-GFP fusion protein was 
transiently transfected into COS7 cells. Upon transfection many cells died before protein 
expression could be induced by doxycycline. 
A fluorescent microscope monitored expression of the GFP reporter twenty-four hours after 
induction. Again, many cells have died upon doxycycline induction. Of the surviving cells, 
expressing either 30 or 95 CGG repeat-RNA, only a small amount showed a GFP signal 
(Figure 2.24 A). However, when compared with the control, it was impossible to distinguish 
if the GFP signal comes from GFP expression within the cells or if it is only auto-
fluorescence of dying cells. Therefore, antibiotic selection against puromycin for establishing 
a stable cell line was not done. 
To test if the low transfection efficiency and the high death rate of the cells depend on the cell 
line used, the same constructs were transfected into HeLa cells (Figure 2.24 B). But similarly 
to the transfected COS7 cells, also many HeLa cells died upon transfection and induction. The 
GFP signal was very weak compared to the control, so it could not be distinguished between 
dying cells that auto-fluoresce or living HeLa cells that express the GFP reporter. 
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Figure 2.24 Co-expression of PP7CP-tagged eGFP and PP7SL-tagged CGG-repeat RNA in COS7 and HeLa cells. The pRTR-PP7 
FMR1 5’UTR (CGG)n vector containing the CGG-repeat RNA with either 30 (top) or 95 CGG (middle) repeats was transiently transfected 
into COS7 (A) and HeLa (B) cells. After induction with doxycycline eGFP signal was analyzed with a fluorescence microscope as indicator 
for successful transfection and CGG-repeat RNA expression. The images of phase contrast and GFP channel were overlayed. The red box 
indicates the region, which is shown as zoom in (on right side). Untransfected cells, which have been treated only with transfection reagent, 
were used as control (bottom). Transfection efficiency was very low compared to the transfection with the initial pRTS-1 vector without 
CGG-repeat RNA. 
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2.2.2.6. Antibody test against αB-crystallin 
In a recent study more than 20 proteins have been found within the inclusions from a 
postmortem FXTAS brain (Iwahashi et al., 2006; Sofola et al., 2007). Proteins identified 
include αB-crystallin, which could therefore be used as an inclusion marker for future 
imaging assays. Fifteen in-house-made antibodies against the C-terminus of αB-crystallin 
were tested on COS7 protein lysate in western blot assays (Figure 2.25). None of the tested 
antibodies did specifically detect αB-crystallin. 
 
 
 
Figure 2.25 Unspecific binding of αB-
crystallin (crys) antibody. Tissue culture 
supernatants (TCS) of 15 different cell 
clones were tested for αB-crystallin (23 
kDa) detection in western blot 
experiments with COS7 protein lysate. 
None of the TCS (lane 2-4, 6-8, 10-12, 14, 
15, 16, 19-21) specifically detected αB-
crystallin. Detection of α-actin (43 kDa) 
served as a loading control (lane 1, 5, 9, 
13, 16, 18). 
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3. Discussion 
3.1. Interaction of Pur-α with nucleic acids 
3.1.1. Affinity for DNA and RNA 
Pur-α I-II shows strong and specific binding to its physiological target MF0677 DNA. 
Located upstream of the c-myc gene (Haas et al., 1995), but much weaker binding to the 
CGG-repeat RNA sequence (Graebsch et al., 2009). For this reason it has been suggested that 
the binding of Pur-α to DNA is stronger than to RNA and as a consequence that there might 
be differences in the binding modes to both nucleic acid targets. However, this study shows 
that Pur-α does not generally bind less effective to RNA than to DNA. Instead, EMSA 
experiments demonstrate that Pur-α has similar binding affinities for DNA and RNA of the 
same sequence. Thus, the higher affinity is observed for MF0677 DNA and RNA sequence 
(KD ~200 nM) (Figure 2.2 A) when compared to CGG-repeat DNA and RNA (KD ~2 µM) 
(Figure 2.2 B). 
Complementing results were obtained from NMR titration assays with 15N-labeled Drosophila 
Pur-α I-II and oligonucleotides. Initial RNA- and DNA-titration trials with the MF0677 and 
CGG-repeat oligomers (24 nt) used in EMSA experiments failed due to precipitation. Most 
likely this was caused by the high protein concentrations and buffer requirements (low pH, 
low salt) needed for NMR measurements. In fact, aggregation of Pur-α/DNA complexes was 
also detectable as higher band shifts in the EMSA experiments (Figure 2.2 A and B). NMR 
titrations with short (5mer) GGN-motif DNA and RNA oligomers that still bound to Pur-α 
with reasonable affinity (Figure 2.3 B) did not induce precipitation. The spectra showed 
similar chemical shift perturbations, regardless of whether it was ssDNA or RNA, indicating 
that both nucleic acids have the same affinity for Pur-α and that they are likely bound in the 
same way (Figure 2.3 C-E). 
Also the crystal structure of Pur-α/DNA co-complex did not provide any evidence why Pur-α 
should have a higher binding affinity for DNA than for RNA. Since a hydroxyl-group on the 
2’ position of the pentose ring of the RNA sugar backbone would not cause steric clashes 
(Figure 2.5) the crystal structure did also not suggest any differences in binding modes 
between DNA and RNA. 
To further understand why Pur-α has a higher affinity for the MF0677 sequence than for pure 
CGG-repeat oligomers and to define its exact binding motif, DNaseI footprint assays were 
performed using the promoter region upstream of the c-myc gene. However, binding to the 
GGN motif within the MF0677 subfragment was not detectable. Several attempts using 
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ssDNA or dsDNA substrates, different protein derivatives comprising only Pur-repeat I-II 
(nucleic acid binding domain) or all three Pur-repeats, or using protein from different species 
(human, Drosophila) did not provide any meaningful results. No Pur-α binding sites were 
detected (Figure 2.15). Therefore, the questions why Pur-α shows such high affinity for the 
MF0677 sequence and how it binds to the c-myc promoter region could not be answered. 
 
 
3.1.2. Stoichiometry of the Pur-α/nucleic acid co-complex 
Stoichiometry of protein/nucleic acid co-complexes can be assessed by several techniques, 
such as NMR (nuclear magnetic resonance) titrations, SAXS (small angle X-ray scattering) 
and ITC (isothermal titration calorimetry). The first two methods have been applied for 
determination of the stoichiometric ratio of a Pur-α/nucleic acid co-complex. 
NMR titration steps resulted in nicely dispersed spectra (Figure 2.3 C-E). However, most 
chemical shift perturbations experienced an intermediate exchange regime. Even 
measurements at higher or lower temperatures (203 K and 293 K) did not alter the exchange 
rate from intermediate to fast or slow. Additionally, by providing an increasing amount of 
nucleic acid the samples tended to aggregate and became more prone to precipitation while 
measuring. Therefore, saturation could not be reached and the stoichiometric ratio of the 
complex could not be determined. 
Since NMR experiments could not be used for stoichiometry determination SAXS 
measurements were performed. Several measurements were done with the MF0677 (24 nt) 
ssDNA and either Pur-α I-II or Pur-α I-III, a dimer in solution. Alike in NMR titration assays, 
polydispers oligomers and aggregates of the Pur-α/nucleic acid co-complex occurred during 
SAXS measurements. Probably again due to the relatively high protein concentration (50-100 
µM) needed for signal detection. Calculation of a stoichiometric ratio was therefore 
impossible. Even when the ionic strength in the buffer was increased from 250 mM to 
500 mM NaCl oligomerisation still occurred. Only 1 M of NaCl prevented aggregation of the 
complex, but unfortunately, also impeded dimerization of Pur-α I-III. Results obtained from 
SAXS measurements were therefore not reliable and could not be used for stoichiometry 
determination. 
ITC represents another possibility for complex analysis. However, also ITC measurements 
require relatively high protein (10-100 µM) and ligand (50-500 µM) concentration for signal 
detection, depending on the KD of the reactants (Duff et al., 2011; Pierce et al., 1999). 
Considering the problems of aggregation and oligomerisation in NMR and SAXS 
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measurements, ITC did not show great promise for successful stoichiometry determination 
and was therefore not explored. 
To overcome the high aggregation and oligomerisation problem, a method was chosen that 
only needs low protein concentrations and is less sensitive to salt concentration or pH of the 
buffer. Though, to determine the complex stoichiometry the nucleic acid concentration needs 
to be above the KD to ensure that all protein is bound. The KD for Pur-α I-II and MF0677 (24 
nt) ssDNA was estimated to be approximately 150 nM (Figure 2.2 A). In a so-called dot blot 
assay Pur-α I-II was titrated to a constant amount (1 µM) of radiolabeled MF0677 (24 nt) 
ssDNA and blotted onto a nitrocellulose membrane. The signal intensities of protein/DNA 
complexes bound to the nitrocellulose membrane were plotted against the protein 
concentration. The saturation curves of three independent experiments clearly showed a 
stoichiometric ratio of 1:2 (Pur-α:DNA) (Figure 2.13). Thus, in solution Pur-α I-II can bind 
two molecules of ssDNA. This result is consistent with the two binding sites observed in the 
crystal structure of Pur-α I-II in complex with ssDNA (Figure 2.5), where the ssDNA 
oligomers become clamped between Pur-repeat I and II. The interacting residues are Q52, 
S53, K54 (QSK I) on Pur-repeat I and K138, N140, R142 (KNR II) on Pur-repeat II. A 
particularly interesting feature of this co-structure is the flipping-out of cytosine C5 and the 
resulting twist of the 3’-end of the DNA strand, which then interacts with a Pur-repeat I of 
another symmetry related protein molecule (K61, R80, D59, Y57 and K70) (Figure 2.5). 
Although both Pur-repeats share a moderate sequence identity (~30 %), share the identical 
binding motif (KNR), and adopt the same fold (Graebsch et al., 2009 & 2010), the second 
binding event on Pur-repeat I appears at overlapping but non-identical residues. 
Crystallographic packing forces might have prevented DNA binding to the identical motif 
(KNR) on Pur-repeat I. One could also speculate that symmetric and asymmetric binding 
depends on the GGN-motif of the nucleic acids. For instance, different motifs (GGA, GGG, 
GGC, GGT) might bind to slightly shifted interaction sites of Pur-α. Moreover, this might 
explain why CGG-repeats bind less strongly to Pur-α than the MF0677 sequence that mostly 
consists of GGA and GGT motifs. 
 
 
3.1.3. Interaction sites of Pur-α 
The Pur-α/DNA crystal structure shows that both Pur-repeats interact with nucleic acids and 
that the DNA strands become clamped between the two repeats. Pur-α mostly interacts with 
the guanine bases. Only R142 and K138 interact with the base of cytosine C2 and the sugar 
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phosphate backbone of cytosine C5, respectively (Figure 2.5 B). Binding therefore occurs 
sequence specific and confirms the GGN binding motif that has already been postulated by 
Bergemann and Johnson, 1992. 
Previous findings implied that the positively charged β-sheets mediate DNA/RNA-binding 
whereas the amphiphatic helices might rather contribute to protein-protein interactions 
(Graebsch et al., 2009). The crystal structure of the protein-DNA co-complex confirms that 
the β-sheets, including their short linkers, are involved in DNA binding, in contrast to the α-
helices that show no interaction with the nucleic acid (Figure 2.5). The residues involved in 
DNA binding are highly conserved (Figure 2.7). Mutation of the interacting residues resulted 
in a decreased binding affinity and therefore confirmed the interaction sites seen in the crystal 
structure (Figure 2.8 A-F). Moreover, a second potential binding site was found on Pur-repeat 
I (KNR I), which upon mutation causes a decrease in binding affinity as seen in EMSA 
experiments (Figure 2.8 G-H).  
Within the crystal lattice the first two DNA bases (G1 and C2) of the 5’-end are base pairing 
with the 5’-end of the symmetry related DNA molecule (Figure 2.5 H). This base pairing 
might be due to crystal packing forces. At least, there is no evidence that the base pairing has 
any physiological relevance. 
Structural comparison of the Pur-α I-II apo-structure (PDB ID 3K44) and the structure of the 
protein-DNA co-complex revealed that Pur-α does not show significant conformational 
changes upon nucleic acid binding (Figure 2.6). 
 
 
3.1.4. Unwinding of dsDNA 
The most interesting feature of Pur-α’s binding mode to ssDNA represents the non-canonical 
twist of the DNA strand. Pur-α is known to unwind dsDNA, but so far it has not been shown 
how this is done in an ATP-independent manner (Darbinian et al., 2001; Wortman et al., 
2005). Here, the crystal structure of the protein/DNA co-complex provides an explanation 
how stabilization of ssDNA is enabled. The phenylalanine F145 (F II) on Pur-repeat II 
undertakes base stacking with the guanine G4 and thereby blocks the space for the 
neighboring cytosine C5 (Figure 2.5 E). Thereupon, the cytosine flips out and the 3’-end of 
the DNA strand becomes distorted. The interaction of the K138 with the phosphate backbone 
of the cytosine enforces this unusual turn (Figure 2.5 B and C), which additionally becomes 
stabilized by binding of the 3’-end to another protein molecule (Figure 2.5 F). F II is highly 
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conserved throughout different species (Figure 2.7). When it becomes mutated to an alanine 
unwinding of dsDNA becomes abolished (Figure 2.12 B). 
In contrast, the general ability of DNA/RNA-binding is only decreased in this mutant (Figure 
2.8. E and F), probably because the main interaction sites (QSK I, KNR II) are sufficient to 
facilitate binding. When the main interaction sites are mutated, nucleic acid binding (Figure 
2.8 C and D) is strongly decreased and consequently unwinding of dsDNA is abolished 
(Figure 2.12 A). Base stacking with a guanine base also occurs on the potential second 
binding site of Pur-repeat I (Figure 2.5 B and G). 
F II has its structural counterpart in position F68 (F I) on Pur-repeat I. Although F I is also 
highly conserved, the guanine base stacking is not mediated by F I, but by another conserved 
residue, the Y57 (Figure 2.5 B and G; Figure 2.7). As mentioned before, the two binding sites 
of Pur-α seen in the crystal structure are asymmetric and might account for sequence specific 
binding to nucleic acids with different GGN motifs. Base stacking of the phenylalanine and 
tyrosine with the guanine bases underlines once more the binding preference of Pur-α to GGN 
motifs (Bergemann and Johnson, 1992). 
Pur-α binds to origins of replication and promoter regions (Bergemann and Johnson, 1992; 
Bergemann et al., 1992) and regulates the transcription of more than 20 genes (White et al., 
2009). Pur-α’s unwinding ability of dsDNA might therefore play an important role in the 
initiation of replication and transcription. In this study, the stoichiometry of Pur-α bound to 
short ssDNA molecules was determined to have a ratio of 1:2 (protein:DNA), but in this 
context it could also be possible that longer ssDNA fragments might wrap around the nucleic 
acid binding domain (Pur-repeat I-II) interacting with the two binding surfaces, seen in the 
crystal structure. 
Moreover, it is still unknown how dsDNA binding to an intermolecular Pur-α dimer providing 
two nucleic acid binding domains occurs. Analysis of the electrostatic surface charges show 
that there are two opposing patches of positively charged residues, one on each Pur-repeat 
(Figure 3.1 A and B). These residues correspond to the interaction sites seen in the crystal 
structure, whereby DNA-binding to Pur-repeat I has only been observed for the symmetry-
related Pur-α molecule within the crystal lattice. However, in solution each Pur-repeat might 
bind to one of the strands of a duplex DNA molecule (Figure 3.1 C). This might be enabled 
through spontaneous openings and re-closings of the dsDNA helix, called DNA breathing, by 
which DNA bases become accessible for DNA-binding proteins such as Pur-α (Peyrard et al., 
2009; Jose et al., 2012). Further separation of the two DNA strands might be caused by the 
intercalating residues (phenylalanine, tyrosine) that undergo the base stacking with the 
guanines and thereby cause the non-canonical twist of the DNA strands. The partly melted 
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duplex DNA could then be further unwound by DNA helicases, which are required for 
initiation of transcription and replication. 
 
 
Figure 3.1 Unwinding model for Pur-α and dsDNA. A: Electrostatic surface model of Pur-α I-II in complex with ssDNA (cyan). Red and 
blue coloration indicate negative and positive electrostatic potentials, respectively. B: Representation as in A, additionally showing the 
ribbon backbone model of Pur-repeat I (green) and II (blue). DNA interaction sites, seen in the crystal structure, are shown as red sticks. C: 
Representation as in A. Model showing dsDNA (cyan) bound to Pur-α I-II. The double-strand is locally unwound and the two separated 
strands bind to the two opposing binding sites on the protein. 
 
Pur-repeat III binds only weakly to DNA and RNA (Figure 2.10) and unwinds dsDNA only 
slightly (Figure 2.12 E) compared to Pur-repeat I-II. On the basis of the crystal structure it 
seems unlikely that Pur-repeat III would interfere with the dsDNA-binding of Pur-repeat I-II, 
since it arranges on the backside of their nucleic acid binding surface (Figure 3.2 A and B). 
Hence, Pur-repeat III might only facilitate dimerization, thereby guiding a second 
DNA/RNA-binding domain (Pur-repeat I-II) to another GGN motif further upstream or 
downstream where additional DNA-unwinding could take place (Figure 3.2 C). 
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Figure 3.2 Pur-repeat III might guide two nucleic acid binding domains to dsDNA. A: Electrostatic surface model of Pur-α I-II in 
complex with ssDNA (cyan). Red and blue coloration indicate negative and positive electrostatic potentials, respectively. Pur-repeat III 
likely arranges at the opposing site of the nucleic acid binding region. B: Representation as in A, additionally showing the ribbon backbone 
model of Pur-repeat I (green) and II (blue) and its C-terminus connecting to Pur-repeat III. DNA interaction sites, seen in the crystal structure, 
are shown as red sticks. C: Schematic drawing of a intermolecular Pur-α dimer (red) bound to dsDNA (cyan). Pur-repeat III mediates 
dimerization, leading both nucleic acid binding domains (repeat I and II) to the duplex DNA where they unwind the strands. 
 
Pur-α binds to CGG-repeats found in the 5’UTR of the fmr1 mRNA (Jin et al., 2007; Sofola et 
al., 2007). CGG-RNA repeats are known to form thermodynamically stable structures by non-
canonical GG pairing (Kiliszek et al., 2011). One interaction partner of Pur-α is the Rm62, the 
Drosophila ortholog of p68 RNA helicase that is implicated in transcriptional regulation, pre-
mRNA splicing, RNA interference and nucleo-cytoplasmic shuttling (Qurashi et al., 2011). 
Hence, another function of Pur-α could be the initial unwinding of dsRNA to allow its 
interacting helicase to subsequently regulate RNA processing, translation and transport. In 
this study, several attempts were made to establish an dsRNA-unwinding assay. Due to 
technical limitiations no suitable dsRNA substrate could be generated. CGG-repeat RNA 
oligonucleotides did not anneal to a dsRNA substrate. Annealing of the CGG-repeat RNA to a 
complementary GCC-strand resulted in a dsRNA substrate, but could not be unwound by Pur-
α, implying that Pur-α needs unpaired nucleotides that provide a contact point for unwinding. 
Hence, Pur-α’s role in unwinding of dsRNA still needs to be analyzed. 
 
 
3.1.5. Pur-α mutations cause 5q31.3 microdeletion syndrome 
Recently, de novo mutations in Pur-α have been found to cause a so-called microdeletion 
syndrome, which is characterized by neonatal hypotonia, encephalopathy and severe 
developmental delay (Lalani et al., 2014). Of the identified mutations two missense mutations 
(K97E, A89P) are of particular interest. Sequence alignment of Pur-α from different species 
shows that the residues A89 and K97 of the human Pur-α protein correspond to the residues 
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A72 and R80 of the Drosophila protein, respectively. These residues are highly conserved 
(Figure 2.7).  
In the crystal structure of the protein/DNA co-complex A72 does not directly interact with the 
DNA molecule but forms backbone hydrogen bonds between the β-strands of Pur-repeat I to 
stabilize the β-sheet (Figure 3.3 A top), which has been shown to be the nucleic acid binding 
surface (this study, Graebsch et al., 2009). Proline is very rigid compared to other amino acids 
and acts as a disruptor for α-helices and β-sheets. When A72 and its counterpart A98 in the 
human protein (Figure 3.3 A middle), are substituted by a proline the backbone interactions 
that stabilize the β-sheet become disrupted (Figure 3.3 A bottom). This likely leads to 
misfolding of the protein and furthermore to abolishment of nucleic acid binding. 
R80 in the Drosophila protein directly binds to the guanine base G7 (Figure 2.5 B and G; 
Figure 3.3 B top). Mutation of R80 has been shown to result in reduced nucleic acid binding 
(Graebsch et al., 2009). The positively charged residue K97 in human Pur-α is analogous to 
Drosophila R80. Most likely also K97 is involved in DNA interaction as modeled in the 
crystal structure (Figure 3.3 B middle). This might explain why a mutation to glutamate, a 
negatively charged residue likely impairing the DNA interaction, causes dysfunction of Pur-α 
(Figure 3.3 B bottom).  
 
As described in chapter 3.1.1. Pur-α binds to DNA and RNA in undistinguishable mode. In 
the previous section it has already been discussed that Pur-α regulates replication, 
transcription and moreover, has been implied to regulate mRNA transport and translation 
(Ohashi et al., 2000; Johnson et al., 2006; Kanai et al., 2004; Aumiller et al., 2012). Hence, 
impaired binding to nucleic acids would lead to misregulation of plenty of cellular functions.  
Taken together, the crystal structure of the Pur-α/DNA co-complex reveals how these two 
missense mutations (K97E, A89P) found in the microdeletion syndrome might have an effect 
on the nucleic binding ability and therefore on the proper function of Pur-α leading to the 
disease phenotype.  
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Figure 3.3 Pur-α mutations found in the 5q31.3 microdeletion syndrome can be modeled into the crystal structure of Drosophila Pur-
α I-II (green) in complex with DNA (cyan). A: Residue A72 of the Drosophila protein (top) corresponds to the residues A89 (grey) of the 
human protein modeled into the Drosophila crystal structure (middle). Both alanines form backbone hydrogen bonds. When A89 is mutated 
to proline, backbone interactions are disrupted (bottom). B:  Residue R80 of the Drosophila protein (top) corresponds to the residues K97 
(grey) of the human protein, which was modeled into the crystal structure (middle). Both R80 and K97 are positively charged residues. R80 
interacts with the guanine G7. The same interaction could also be mediated by K97. Mutation of K97 to a glutamate would impair DNA 
binding due to its negative charges (bottom). D.m.: Drosophila melanogaster; H.s.:Homo sapiens. 
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3.2. Outlook 
3.2.1. Doxycycline-inducible CGG-repeat/reporter expression system - Cellular 
FXTAS model 
FXTAS is caused by moderate expansions (55-200 repeats) of a CGG trinucleotide in the 
5’UTR of the fmr1 gene. The major neuropathological hallmark for FXTAS is intranuclear, 
neuronal and astrocytic inclusions throughout the brain (Greco at al., 2006; Iwahashi et al., 
2006). Analyses on the inclusions from post-mortem brain tissues revealed association with 
fmr1 mRNA and more than 20 proteins, including Pur-α (Iwahashi et al., 2006; Sofola et al., 
2007 Jin et al., 2007). To date Pur-α’s role in the disease pathomechanism is not understood. 
In pull down experiments from different tissues (mouse and human neurons, COS7 and HeLa 
cells) with biotinylated RNA Pur-α has been shown to bind to CGG-repeat RNA (Jin et al., 
2007; Sofola et al., 2007). However, in these experiments RNA-binding might occur via 
protein-protein rather than via direct protein-RNA interaction or might be induced by 
unnaturally high concentrations of the RNA. To date no protein-interaction partner of Pur-α 
has been identified that could mediate Pur-α’s sequestration into the inclusions. 
Expression of CGG-repeat RNA (with 60 or more repeats) in COS7 cells has been shown to 
result in formation of nuclear inclusions (Sellier et al., 2010), which can be purified from 
nuclear extracts. Based on this, stable cell lines expressing normal and FXTAS-related CGG 
repeat RNA would help to identify proteins that directly bind to the CGG-repeat RNA and to 
validate that Pur-α is amongst these proteins. By performing in vivo cross-linking of the 
CGG-repeat RNA with its bound proteins, the cross-linked RNA-protein complexes could be 
isolated and subsequently analyzed by mass spectrometry. Furthermore, findings for cells 
expressing normal and disease-related repeat RNA could be compared. This way, it would 
also be possible to identify potential protein interaction partners of Pur-α in the disease 
context. 
Towards this goal, I generated mammalian vector constructs (pRTS-1 and pRTR), expressing 
the fmr1 5’UTR, followed by either 30 (normal repeat length) or 95 (FXTAS-related repeat 
length) CGG repeats, which can be applied for the establishment of a stable cell line (Figure 
2.21). Special features of these vectors are the inducible bi-directional promoter, the eGFP 
reporter, the two-component system (PP7 coat protein binding to PP7 stem loops) for RNA-
isolation and, only present in the pRTR vector, a cell surface protein (CD2) that enables cell 
selection via magnetic beads that are coupled to the respective antibody (see chapter 2.2.2.2.). 
Test transfections of the empty vectors (pRTS-1 and pRTR) in COS7 cells were successful, 
meaning the expression of the eGFP reporter could be induced and the eGFP signal could be 
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monitored by fluorescence microscopy (Figure 2.22). However, first attempts of generating a 
stable cell line expressing only the CGG-repeat RNA (pRTS-1) in COS7 cells were not 
satisfactory (Figure 2.23). After several weeks of selection, cells were resistant to the 
antibiotic, but only few cells expressed the reporter GFP upon induction. Either the cells have 
integrated only the antibiotic resistance gene into their genome or the GFP reporter together 
with the CGG-repeats became silenced. A faster and maybe more reliable alternative to 
antibiotic cell selection is FACS (Fluorescence-activated cell sorting). FACS is a laser-based, 
biophysical technology, which can be employed in cell sorting by suspending cells in a stream 
of fluid and passing them by an electronic detection apparatus. Based on the specific light 
scattering and fluorescent characteristics cells of interest can be sorted from a heterogeneous 
mixture. Here, using the eGFP signal to perform cell selection via FACS could not be applied 
because induction of the GFP reporter also induces the expression of the CGG-repeat RNA 
and cells containing disease-related repeat length (95 CGG) show decreased cell viability and 
die 72-96 hours post induction (Arocena et al., 2005; Hoem et al., 2011;Selier et al., 2010). 
To avoid this problem the second vector construct (pRTR) was used enabling cell selection 
via magnetic beads coupled to an antibody against the cell-surface protein CD2. However, 
upon transfection of the pRTR vector, containing CGG-repeat RNA, GFP reporter and the 
PP7 two-component system for RNA-isolation, many COS7 cells died before protein 
expression could be induced. Also, the eGFP signal was not distinguishable from auto-
fluorescence of dying cells (Figure 2.24 A). Overall, the more components the vectors 
contained and the larger the size of the vector, the more cells were prone of dying during 
transfection. This effect was not cell specific, since transfection of HeLa cells with the same 
construct showed the same result (Figure 2.24 B). For time limitations, this problem has not 
been resolved and therefore, cell selection for establishing a stable cell line has not been done, 
yet.  
Taken together, the stable cell lines expressing CGG-repeat RNA could not be established, 
but the necessary vector constructs for expression of normal and disease-related CGG-repeat 
RNA have been generated (Figure 2.21). Only transfection and selection methods have to be 
further improved to obtain a stable cell line with strong eGFP and CGG-repeat RNA 
expression, respectively. 
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3.2.2. Pur-α’s role in transcription 
Pur-α is involved in transcription of several neuronal genes including the myeline basic 
protein (Mbp) gene (Darbinian et al., 2001; Haas et al., 1995) and the myelin proteolipid 
protein 1 (Plp1) gene (Dobretsova et al., 2008), both responsible for myelination of nerve 
cells in the central nervous system (CNS). Pur-α deficient (PURA -/-) mice develop severe 
neurological problems and die within a few weeks after birth (Khalili et al., 2003). Still, Pur-
α’s role in transcription and why a lack of Pur-α is lethal in knockout mice has to be 
elucidated. Chip-Seq (chapter 2.2.1.1.) experiments with Pur-α could reveal which genes 
become activated by Pur-α, whether they share a consensus sequence and if they can be 
classified into sub-categories. Moreover, such findings would also contribute to understand 
why Pur-α deficient mice suffer from severe neurological defects and die shortly after birth. 
In this study, BAC (bacterial artificial chromosome) constructs were generated to establish a 
stable cell line expressing either N-terminally or C-terminally eGFP-tagged human Pur-α 
(Figure 2.18). Tagging of Pur-α was necessary, since tested anti-Pur-α antibodies did not 
show specificity and would cross-react with other members of the Pur-family (Figure 2.17). 
A Pur-α BAC clone was chosen because it contains the genomic Pur-α promoter and 
regulatory sequences. This way, tagged Pur-α protein expression underlies the same 
regulation as the protein expression of the endogenous Pur-α gene and does not have to be 
induced artificially. The BAC constructs were transfected into HeLa cells and subsequently 
selected for antibiotic resistance to establish a stable cell line. Again, after several weeks of 
selection, antibiotic resistant colonies were obtained (Figure 2.19). However, expression of 
eGFP-tagged Pur-α could neither be detected in Western Blot assays (Figure 2.20) nor by 
fluorescence microscopy. This can be explained by either silenced eGFP-Pur-α expression or 
by exclusion of the eGFP-Pur-α gene from the genome during cell selection, while 
maintaining the antibiotic resistance. Since antibiotic selection seems to be insufficient for 
generating the stable cell line, future clone selections will be done by performing FACS. The 
eGFP signal will facilitate to sort the cells expressing eGFP-tagged Pur-α and to accumulate 
positive clones for further amplification and establishment of a stable cell line. 
 
 
3.2.3. Expression of Pur-α mutants in the FXTAS Drosophila model 
Jin et al have generated transgenic Drosophila flies that selectively express FXTAS-related 
CGG-repeat RNA in the eyes (Jin et al., 2003). These flies show a CGG-mediated eye 
neurodegeneration phenotype, which can be rescued by overexpression of Pur-α. Furthermore, 
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Pur-α co-localizes in nuclear inclusions induced by CGG-RNA expression in the fly model (Ji 
et al., 2003; Jin et al., 2007; Sofola et al., 2007). 
In this study, the crystal structure of the Pur-α/DNA co-complex revealed the residues that are 
involved in nucleic acid binding. Binding assays with mutant Pur-α further confirmed the 
interaction sites seen in the crystal structure. To test whether these Pur-α mutants also have an 
effect in vivo, I am collaborating with the Jin lab to use the FXTAS fly model for mutant Pur-
α expression. For this purpose, I generated vectors containing the full length Drosophila Pur-
α gene harboring the respective mutations: OSK I - KNR II, F II, KNR II (Chapter 2.1.4.2.) 
and R80A/R158A (Graebsch et al., 2009). These vectors are currently used in Jin’s lab to 
generate transgenic flies expressing mutant Pur-α together with CGG-repeat RNA in the fly’s 
eyes. Once these flies are established, they will be first studied by light-microscopic analysis 
of the facette eyes and then further investigated by using several techniques, such as confocal 
imaging and transmission electron microscopy of brain sections as well as 
immunohistochemistry and SEM (scanning electron microscopy) of fly eyes. 
The generated transgenic flies could answer the following questions: Do the mutations of Pur-
α weaken the nucleic acid binding ability also in vivo and thereby impair Pur-α‘s normal 
function? Does mutant Pur-α have an effect on nuclear inclusion formation? Does mutant Pur-
α become sequestered into the nuclear inclusions? Can mutant Pur-α still rescue the eye 
neurodegeneration phenotype? Since one mutant was primarily defective in its unwinding 
activity, it might also be possible to distinguish between different functions.  
In summary, my structure-to-functional analysis should yield a comprehensive understanding 
of Pur-α’s binding mode to nucleic acids and therefore its function in cellular processes, such 
as transcription, where unwinding of duplex DNA might be essential for transcription 
regulation. Furthermore, my results might help to understand Pur-α’s role in 
neurodegenerative diseases, such as FXTAS. Here, RNA-binding might lead to sequestration 
into the inclusions and loss of unwinding might even contribute to pathogenesis of this 
disease. 
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4. Materials and Methods 
4.1. Consumables and chemicals 
All common chemicals used were purchased from Merck (Darmstadt, Germany), Roth 
(Karlsruhe, Germany), Roche (Mannheim, Germany) and Sigma-Aldrich (Hamburg and 
Seezle, Germany), unless stated otherwise. Enzymes and nucleotides for molecular biology as 
well as molecular weight markers and loading dyes for gel electrophoresis were ordered from 
Fermentas (St. Leon-Rot, Germany), New England Biolabs (Frankfurt, Germany) and 
Invitrogen (Karlsruhe, Germany). Reagents for bacterial cell cultures were obtained from 
Becton, Dickinson & Co (Heidelberg, Germnay) and Sigma Aldrich. Media for mammalian 
cell culture was purchased from Invitrogen. Chromatography was performed with materials 
and columns of GE Healthcare (Munich, Germany). Radioactive nucleotides (γ-32P-ATP) for 
labeling of nucleic acids were obtained from Hartmann Analytic (Braunschweig, Germany). 
DNA and RNA oligonucleotides were ordered from Eurofins MWG (Ebersberg, Germany) 
and Thermo Fisher (Ulm, Germany). Crystallization screens, tools and reagents were 
purchased from Hampton Research (Aliso Viejo, USA) and Qiagen  (Hilden, Germany). 
 
4.2. Oligonucleotides 
4.2.1. DNA oligonucleotides for cloning 
No. Name Sequence 5’-3’ 
1 PurA-KNRII-for GTATTACTTGGACTTAGCAGAAGCTGCGGCTGGCCGATTTTTACG 
2 PurA-KNRII-rev CGTAAAAATCGGCCAGCCGCAGCTTCTGCTAAGTCCAAGTAATAC 
3 PurA-F145A for GAAAATGCGCGTGGCCGAGCTTTACGGGTATCGCAAAC 
4 PurA-F145A rev GTTTGCGATACCCGTAAAGCTCGGCCACGCGCATTTTC 
5 PurA-R80A for GATTGGCGCTGATGGTAGAGCAAGTCAAATTTACTTGGC 
6 PurA R80A rev GCCAAGTAAATTTGACTTGCTCTACCATCAGCGCCAATC 
7 PurA-R158A for CAATAACAAGAGGGGGGCCTGCATCTCAAATCGCTTTACCG 
8 PurA-R158 rev CGGTAAAGCGATTTGAGATGCAGGCCCCCCTCTTGTTATTG 
9 PurA-QSK for1 GCGTGCAGAGATTTCAATGCTTGAAG 
10 PurA-QSK-G-revMut CGTCCACCTCCTATTTGCAACATTTTC 
11 PurA-QSK-G-forMut AATAGGAGGTGGACGATTTTATTTGGATG 
12 PurA-QSK rev1 GAGGCAGATCGTCAGTCAGTCAC 
72 PurA-KNR I for mut GTAGCACAAGCTAGAGCAGGCCGTTTTAT 
73 PurA-KNR I rev mut  GCCTGCTCTAGCTTGTGCTACATCCAAAT 
74 PurA-KNR I rev1 GAGGCAGATCGTCAGTCAGTCACG 
13 PurA-F68A-for GAAGAGGCCGTGCTATAAAGGTTGC 
14 PurA-F68A-rev GCAACCTTTATAGCACGGCCTCTTC 
15 PP7CP-SwaIfor AAAATTTAAATATGTCCAAAACCATCGTTCTTTCGGTCGG 
16 PP7CP-SwaIrev TTTATTTAAATTACGGCCCAGCGGCACAAG 
Table 4. 1 DNA oligonucleotides for cloning 
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4.2.2. DNA oligonucleotides for interaction studies and crystallization 
No. Name Sequence 5'-3' 
53 GGN TCAGAGCCGCCACCCTCA 
54 Fluo-SL DNA FAM-CCAGGGCACTTAAAAAAATTCGCCTGG-DAB 
57 CGG DNA (24nt) CGGCGGCGGCGGCGGCGGCGGCGG 
55 CGG DNA (7nt) GCGGCGG 
88 Fluo-MF0766-5’end (7nt) GTGGTGG-fluorescein 
89 Fluo-MF0677-3’end (7nt) AGAGAAA-fluorescein 
58 MF0677 DNA (24nt) GGAGGTGGTGGAGGGAGAGAAAAG 
62 myc-MF0677 (150nt) 
AACTCAACGGGTAATAACCCATCTTGAACAGCGTACATGCTATAC
ACGCACCCCTTTCCCCCGAATTGTTTTCTCTTTTGGAGGTGGTGGA
GGGAGAGAAAAGTTTACTTAAAATGCCTTTGGGTGAGGGACCAAG
GATGAGAAGAATGT 
63 myc-MF0677-revC (150nt) 
ACATTCTTCTCATCCTTGGTCCCTCACCCAAAGGCATTTTAAGTAA
ACTTTTCTCTCCCTCCACCACCTCCAAAAGAGAAAACAATTCGGGG
GAAAGGGGTGCGTGTATAGCATGTACGCTGTTCAAGATGGGTTATT
ACCCGTTGAGTT 
71 NMR DNA (5nt) GCGGA 
Table 4. 2 DNA oligonucleotides for interaction studies and crystallization 
 
4.2.3. RNA oligonucleotides for interaction studies and crystallization 
No. Name Sequence 5'-3' 
51 CGG (25nt) GCGGCGGCGGCGGCGGCGG 
52 Fluo-SL RNA FAM-CCAGGGCACUUAAAAAAAUUCGCCUGG-DAB 
56 CGG RNA (7nt) GCGGCGG 
59 CGG RNA (24nt) CGGCGGCGGCGGCGGCGGCGGCGG 
60 MF0677 RNA (24nt) GGAGGUGGUGGAGGGAGAGAAAAG 
61 (G4C2)4 (24nt) GGGGCCGGGGCCGGGGCCGGGGCC 
Table 4. 3 RNA oligonucleotides for interaction studies and crystallization 
 
 
4.3. Plasmids 
4.3.1. Commercial plasmids 
Name Application Tag Antibiotic Source 
pGEX-6P-1 protein expression in bacteria GST Amp GE Healthcare 
M13mp18 ssDNA DNA unwinding assay - - New England Biolabs 
pEX-A-MF0677 DNase I footrint - Amp Eurofins MWG 
Table 4. 4 Commercial plasmids 
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4.3.2. Plasmids for recombinant protein expression in E. coli 
No. Name/Insert* Vector Primer Restriction sites Template Note 
1 dmPurA 40-185  pGEX-6P-1 - BamHI/XhoI - a) 
2 dmPurA 40-255 pGEX-6P-1 - BamHI/XhoI - a) 
4 dmPurA 40-185 I69M pGEX-6P-1 39/40 BamHI/XhoI 1  
5 dmPurA 40-185 S88M pGEX-6P-1 43/44 BamHI/XhoI 1  
6 dmPurA 40-185 L135M pGEX-6P-1 47/48 BamHI/XhoI 1  
7 dmPurA 40-185 F145A pGEX-6P-1 3/4 BamHI/XhoI 1  
8 dmPurA 40-185 F68A pGEX-6P-1 13/14 BamHI/XhoI 1  
9 dmPurA 40-185 QSK I – KNR II pGEX-6P-1 9/10/11/12 BamHI/XhoI 11  
10 dmPurA 40-180 KNR I pGEX-6P-1 9/72/73/74 BamHI/XhoI 1  
11 dmPurA 40-185 KNR II pGEX-6P-1 1/2 BamHI/XhoI 1  
12 dmPurA 40-185 R80A pGEX-6P-1 5/6 BamHI/XhoI 1  
13 dmPurA 40-185 R80A/R158A pGEX-6P-1 7/8 BamHI/XhoI 12  
14 dmPurA 185-260 pGEX-6P-1 - BamHI/XhoI - a) 
15 hPurA 56-287 C272S pGEX-6P-1 - BamHI/XhoI - b) 
Table 4. 5 Plasmids for recombinant protein expression in E. coli 
 
*dmPurA refers to D.melanogaster Pur-α, hPurA refers to human Pur-α. The numbers in the name indicate the start and stop site of 
the amino sequence. 
a) Created by Dr. Almut Graebsch, Gene Center Munich (Germany)  
b) Obtained from Prof. Dierk Niessing, Helmholtz Zentrum München (Germany) 
 
4.3.3. Plasmids for RNA/protein expression in mammalian cell lines 
No. Name Vector Insert* Restriction sites Template Note 
17 pRTS-1 pRTS-1 - - - a) 
18 pRTS-1_30CGG pRTS-1  fmr1 5’UTR-(CGG)30 XhoI/BlpI 46  
19 pRTS-1_95CGG pRTS-1  fmr1 5’UTR-(CGG)95 XhoI/BlpI 47  
20 
pRTS-
1_30CGG_PP7 pRTS-1  
27xPP7 SL, fmr1 5’UTR-
(CGG)30, 
eGFP-PP7 CP 
SfiI (PP7 SL-fmr1 5’UTR-
(CGG)n) 
AscI/SwaI (eGFP-PP7 CP) 
46/43/44  
21 
pRTS-
1_95CGG_PP7 
pRTS-1  
27xPP7 SL, fmr1 5’UTR-
(CGG)95, 
eGFP-PP7 CP 
SfiI (PP7 SL-fmr1 5’UTR-
(CGG)n) 
AscI/SwaI (eGFP-PP7 CP) 
47/43/44  
22 
pRTS-
1_30CGG_PP7SL 
pRTS-1  
27xPP7 SL, fmr1 5’UTR-
(CGG)30 
SfiI 
 
46/43 
 
23 
pRTS-
1_95CGG_PP7SL 
pRTS-1  
27xPP7 SL, fmr1 5’UTR-
(CGG)95 
SfiI 
 
47/43 
 
25 pUC19-SfiI pUC19 - - - a) 
26 pUC-30CGG pUC19 fmr1 5’UTR-(CGG)30 EcoRV 46  
27 pUC-95CGG pUC19 fmr1 5’UTR-(CGG)95 EcoRV 47  
28 pUC-
30CGG_PP7SL 
pUC19 
27xPP7 SL, fmr1 5’UTR-
(CGG)30 
BamHI (PP7 SL) 
EcoRV (fmr1 5’UTR-
(CGG)30 
46/43 
 
29 
pUC-
95CGG_PP7SL pUC19 
27xPP7 SL, fmr1 5’UTR-
(CGG)95 
BamHI (PP7 SL) 
EcoRV (fmr1 5’UTR-
(CGG)95 
47/43  
31 pRTR-CD2-NIG pRTR - - - a) 
50 
pRTR-
1_30CGG_PP7 
pRTR 
27xPP7 SL, fmr1 5’UTR-
(CGG)30, 
eGFP-PP7 CP 
SfiI (PP7 SL-fmr1 5’UTR-
(CGG)n) 
AscI/SwaI (eGFP-PP7 CP) 
20  
51 
pRTR-
1_95CGG_PP7 pRTR 
27xPP7 SL, fmr1 5’UTR-
(CGG)95, 
eGFP-PP7 CP 
SfiI (PP7 SL-fmr1 5’UTR-
(CGG)n) 
AscI/SwaI (eGFP-PP7 CP) 
21  
43 pCR4-24xPP7-SL  pCR4 24xPP7 SL BamHI/? - b) 
44 
pET22HT-
PP7delFG  
pET22 
PP7 CP  - 
b) 
46 
pCEP4-TRE-T-
30-EGFP2 pCEP4 
fmr1 5’UTR-(CGG)30 XhoI/BlpI - c) 
47 
pCEP4-TRE-T-
95-EGFP2 
pCEP4 fmr1 5’UTR-(CGG)95 XhoI/BlpI - c) 
Table 4. 6 Plasmids for RNA/protein expression in mammalian cell lines 
 
*SL refers to stem loop, CP refers to coat protein. 
a) provided by Prof. Georg Bornkamm, Helmholtz Zentrum München (Germany) 
b) provided by Prof. Ralf Jansen, MPI Tübingen (Germany) 
c) provided by Prof. Flora Tassone, UC Davis (USA) 
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4.4. BAC (Bacterial artificial chromosome) clone, tagging cassettes, tagging 
and verification oligonucleotides 
BAC name Vector Insert length (bp) Gene start Gene end Source 
RP11-1106D15 pBAC 3.6 
Chromosome 5 
genomic sequence 
of human Pur-alpha 
flanked by 
regulatory regions 
180122 131561 140520 
Empire Genomics 
(Buffalo, USA) 
Table 4. 7 BAC clone 
 
 
Tagging cassette  Tag Source 
N-term: R6K-NFLAP eGFP/PreScission site/S-peptide/TEV site/ Dr. Ina Poser, MPI Dresden (Germany) 
C-term: R6K-LAP Tev site/S-peptide/PreScission site/eGFP Dr. Ina Poser, MPI Dresden (Germany) 
Table 4. 8 Tagging cassettes 
 
Tagging oligonucleotide Sequence 5’-3’ 
N-term GFP tag for 
GCGGCGGGCGGAGCGGCAGGCGGCGGCGGCGCGGCAGCGGAGCGCAGCATCATG
GTGTCCAAGGGCGAGGAACTG 
N-term GFP tag rev 
GCCCGAACCCAGCGCCGCACCACCCTGCTCGCTGCCGCTGTCTCGGTCCGCGGCCC
TGGGCAGGTCGTCGGTCAG 
C-term GFP tag for 
CCGCCGCTGCCACCCTGCTACTGCAGGGTGAGGAAGAAGGGGAAGAAGATGATTA
TGATATTCCAACTACTG 
C-term GFP tag rev 
TGTGTGTGTGTATGCATGTGTGTGTGTGTGGGGGTTTCATTCAGTTTGATTCAGAAG
AACTCGTCAAGAAG 
Table 4. 9 Tagging oligonucleotides 
 
 
Verification oligonucleotide Sequence 5’-3’ 
N-term verify for CCTGAAGTTCATCTGCACCA 
N-term verify rev CCTTCAGCTCGATCCTGTTC 
C-term verify for GTGTTTATGCGAGTGAGCGA 
C-term verify rev AGTTGGTGGAGGTTCTGTGG 
Table 4. 10 Verification oligonucleotides 
 
 
4.5. E. coli strains 
Table 4. 11 E. coli strains 
 
 
4.6. Mammalian cell lines 
Name Description Source 
HeLa (Henrietta Lacks) Human epithelial cells from cervical carcinoma 
Obtained from Dr. Marta Pabis, 
Helmholtz Zentrum München 
(Germany) 
COS7 Fibroblast-like cells from african green monkey kidney tissue 
Provided by Prof. Daniel Krappmann, 
Helmholtz Zentrum München 
(Germany) 
Table 4. 12 Mammalian cell lines 
Name Genotype Source 
XL-1 Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F’ proAB lac1q ZΔM15Tn10 (Tetr)] Stratagene (La Jolla, USA) 
BL21 Star (DE3) 
B F- ompT hsdS(rB
-mB
-) dcm+ Tetr galλ (DE3) 
EndA Hte [argU ile Y leu W Camr] 
Stratagene (La Jolla, USA) 
B834 (DE3) F- ompT gal met rBmB Novagen (Schwalbach, Germany) 
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4.7. Media and supplements for bacterial cell culture 
Medium Composition 
LB (Luria-Bertani medium) 
1 % (w/v) bacto tryptone, 0.5 % (w/v) bacto yeast extract, 0.5 % (w/v) NaCl, 
add 1.5 % (w/v) agar for plates 
SeMet Medium 
7.5 mM (NH4)2SO4, 8.5 mM NaCl, 55 mM KH2PO4, 100 mM K2HPO4, 1 mM MgSO4, 20 mM 
glucose, 1 mg/l CaCl2, 1 mg/l FeCl2, 1 µg/l of the following trace element: Cu2+; Mn2+; Zn2+; MoO4 
2+, 1 mg/l Thiamine, 1 mg/l Biotin, 100 mg/l of the following amino acids (L-alanine, L-arginine, L-
aspartic acid, L-cysteine, L-glutamate, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-
phenylalanine, L-proline, L-serine, L-threonine, L-tyrosine, L-valine, L-selenomethionine 
NMR Medium  
33.7 mM Na2HPO4-2H2O, 22 mMl KH2PO4, 8.55 mM NaCl, 9,35 mM 
15NH4Cl, 0.4 % (w/v) 
glucose, 1 mM MgSO4, 0.3 mM CaCl2, 1 µg biotin, 1 µg thiamin and trace elements as follows: 50 
mg/l EDTA, 8.3 mg/l FeCl3-6H2O, 0.84 mg/l ZnCl2, 0.13 mg/l CuCl2-6H2O, 0.1 mg/l H3BO3, 0.016 
mg/l MnCl2-4H2O 
Table 4. 13 Media for bacterial cell culture 
 
Supplements Application Final concentration 
Ampicillin E. coli selection 100 µg/ml 
Kanamycin E. coli selection 50 µg/ml 
Chloramphenicol E .coli selection 34 µg/ml 
IPTG (Isopropyl-β-D-
thiogalactopyranosid) 
Induction of protein expression in E. coli 0.25 mM 
Table 4. 14 Supplements for bacterial cell culture 
 
 
4.8. Medium, supplements and reagents for mammalian cell culture 
Medium Composition Application 
Complete Medium (v/v) 90 % DMEM, (v/v) 10 % FBS, 100 U/ml penicillin/streptomycin Normal cell culture 
Reduced serum medium (v/v) 100 % OptiMEM Transfection 
Freezing medium 
(v/v) 70 % DMEM, (v/v) 20 % FBS, 100 U/ml Pen/Strep, (v/v) 10 % 
DMSO 
Cell freezing 
Table 4. 15 Media for mammalian cell culture 
 
Supplements Application Final concentration Source 
Gibco® DMEM (4.5 g/l 
glucose, L-glutamine, phenol 
red) 
Cell culture (v/v) 70 or 90 % Invitrogen (Karlsruhe, Germany) 
Gibco® OptiMEM (L-
glutamine, phenol red) 
Transfection (v/v) 100 % Invitrogen (Karlsruhe, Germany) 
FBS (fetal bovine serum) Cell culture (v/v) 10  or 20 % Invitrogen (Karlsruhe, Germany) 
Penicillin / Streptomycin 
(Pen/Strep) Antibiotic / cell culture 100 U/ml Invitrogen (Karlsruhe, Germany) 
DMSO (Dimethylsulfoxid) Cell freezing 10 % (v/v) 
Sigma-Aldrich (Hamburg and 
Seezle, Germany) 
0.5 % Trypsin-EDTA Cell splitting (v/v) 0.05 % Invitrogen (Karlsruhe, Germany) 
Doxycycline hyclate  Induction of gene expression 1 µg/ml 
Sigma-Aldrich (Hamburg and 
Seezle, Germany) 
Geneticin (G418) Cell selection 50-500 µg/ml Invitrogen (Karlsruhe, Germany) 
Hygromycin B Cell selection 50-500 µg/ml Invitrogen (Karlsruhe, Germnay) 
1x PBS (phosphate-buffered 
saline) 
Cell wash 1x Invitrogen (Karlsruhe, Germany) 
Table 4. 16 Supplements for mammalian cell culture 
 
Reagents Application Source 
FuGENE HD Transfection Promega (Mannheim, Germany) 
Lipofectamine® 2000 Transfection Invitrogen (Karlsruhe, Germany) 
Table 4. 17 Reagents for mammalian cell culture 
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4.9. Antibodies 
Primary antibody Clonality / Source Dilution / Application Source 
Anti-α-actin Monoclonal / mouse 1:1000 / western blot Millipore (Schwalbach, Germany) 
Anti-GFP Monoclonal / mouse 1:1000 / western blot 
Covance/Hiss Diagnostics (Freiburg, 
Germany) 
Anti-human-Pur-alpha Monoclonal / mouse 1:200 /western blot Santa Cruz (Heidelberg, Germany) 
Anti-human-Pur-alpha 
(1D7, 3C12, 4E2) 
Monoclonal / rat 1:50 / western blot 
Dr. Elisabeth Kremmer, Helmholtz 
Zentrum München (Germany) 
αB-crystallin 
(17H8, 19D10, 7E2, 
5B2, 13F3, 23E6, 2H4, 
19E6, 18D5, 7F7, 2B3, 
22F8, 2E1, 20D2, 9C8) 
Monoclonal / rat 1:50 / western blot 
Dr. Elisabeth Kremmer, Helmholtz 
Zentrum München (Germany) 
Table 4. 18 Primary antibodies 
 
Secondary antibody Clonality / Source Dilution /Application Source 
Anti-mouse-HRP Polyclonal / goat 1:3000 / western blot BioRad (Munich, Germany) 
Anti-rat-HRP Monoclonal / mouse 1:2000 / western blot 
Dr. Elisabeth Kremmer Helmholtz 
Zentrum München (Germany) 
Table 4. 19 Secondary antibodies 
 
 
4.10. General buffers and stock solutions 
Name Composition Application 
4x stacking gel buffer 0.5 M Tris, (w/v) 0.4 % SDS, pH 6.8 SDS PAGE 
4x separating gel buffer 3 M Tris, (w/v) 0.4 % SDS, pH 8.5 SDS PAGE 
10x TGS 0.25 M Tris, (w/v) 1 % SDS, 1.9 M glycine SDS PAGE 
4x loading dye 
110 mM Tris/HCl pH 6.8, (v/v) 40 % glycerol, (w/v) 0.5 % 
bromophenol blue, (w/v) 4 % SDS, 40 mM DTT SDS PAGE 
Coomassie staining solution 
(v/v) 50 % ethanol, (v/v) 7 % acetic acid, (w/v) 0.2 % 
Coomassie Brilliant blue R-250 
SDS PAGE 
1x TBE 8.9 mM Tris, 8.9 mM boric acid, 2 mM EDTA (pH 8.0) Native PAGE 
Formamide loading dye 
(v/v) 80 % deionized formamide, 1 mg/ml xylene cyanol, 1 
mg/ml bromphenol blue 
Denaturing 
polyacrylamide/TBE gel 
electrophoresis  
50x TAE 2 M Tris-base, (v/v) 5.71 % acetic acid, 50 mM EDTA (pH 8.0) 
Agarose gel 
electrophoresis 
10x PBS 
80 g NaCl, 2 g KCl, 14,2 g Na2HPO4, 2,4 g KH2PO4 in 1 l H2O; 
pH 7,4 
Western blotting 
PBS-T 1x PBS, 1:1000 Tween®20 Western blotting 
10x Semi-dry transfer buffer 30 g Tris, 113 g Glycine in 1 l H2O Western blotting 
1x Semi-dry transfer buffer (v/v) 10 % semi-dry transfer buffer (10x), (v/v) 20 % methanol  Western blotting 
Blocking buffer PBS-T, (w/v) 5 % milk powder Western blotting 
2x magic mix 
(w/v) 48 % Urea, 15 mM Tris-HCl pH 7.5, (v/v) 8.7 % glycerol, 
(w/v) 1 % SDS, (w/v) 0.004% bromophenolblue, 143 mM β-
mercaptoethanol (add fresh) 
Western blotting 
Table 4. 20 General buffers and stock solutions 
 
 
4.11. Molecular biology 
4.11.1. Cloning 
Cloning was done by standard methods as described in Sambrook and Russell 2001. Target 
genes were amplified by polymerase chain reaction (PCR). PCR products were separated by 
agarose gel electrophoresis in 1x TAE buffer, stained with GelRed (Biotium, Hayward, USA) 
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and subsequently purified with the NucleoSpin® PCR clean up kit (Macherey-Nagel, Düren, 
Germany). After digestion with restriction enzymes, DNA fragments were ligated into 
linearized and dephosphorylated vectors (FastAP, Fermentas, St. Leon-Roth, Germany). 
Restriction enzymes and buffers were used according to the manufacturer’s protocols. Point 
mutations were introduced using either the QuickChange II Site-Directed Mutatgenesis Kit 
(Agilent Technologies, Waldbronn, Germany) or by PCR-based site-directed mutagenesis 
(Ho, Hunt et al. 1989). Cloned constructs and sequences of the corresponding 
oligonucleotides used are described in chapter 4.2. and 4.3, respectively. Nucleic acid 
concentrations were measured with NanoDrop Spectrophotometer (Thermo Fisher, Ulm, 
Germany) at 260 nm.   
 
4.11.2. Transformation of E. coli and isolation plasmid DNA 
Chemically competent E. coli cells were prepared according to Hanahan 1983. Plasmid DNA 
was transformed as described in Sambrook and Russell 2001. Transformants were selected by 
antibiotic resistence on LB agar plates. A single colony was used to inoculate 5 ml LB 
medium supplemented with respective antibiotics and grown over night at 37 °C. Plasmid 
DNA was isolated using the NucleoSpin® Plasmid kit (Macherey-Nagel, Düren, Germany) 
according to the manufacturer’s protocol. 
Cloned vector constructs were verified by PCR, restriction digestion or sequencing through 
Eurofins MWG (Ebersberg, Germany). 
 
 
4.12. Bioinformatics 
4.12.1. Protein parameters  
Physical and chemical protein parameters were determined with the ExPASy Proteomics 
Server (http://web.expasy.org/protparam). The molar extinction coefficient, molecular weight 
and isoelectric point of protein fragments were calculated with the ProtParam tool (Gasteiger 
et al. 2005). Protein concentrations were calculated from the absorption at 280 nm measured 
with NanoDrop Spectrophotometer (Termo Fisher, Ulm, Germany) and the respective 
extinction coefficient according to the Lambert-Beer law (Eλ = ελ*c*d). 
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4.12.2. Nucleic acid parameters and primer design  
The molar extinction coefficient and the molecular weight for oligonucleotides were either 
provided by the supplier (MWG, Thermo Fisher) or determined with the OligoCalc server 
(http://www.basic.northwestern.edu/biotools/oligocalc.html) (Kibbe, 2007) or the IDT 
Biophysics server (http://biophysics.idtdna.com/UVSpectrum.html). Concentrations were 
calculated from the absorption at 260 nm measured with NanoDrop Spectrophotometer and 
the respective extinction coefficient according to the Lambert-Beer law (Eλ = ελ*c*d). The 
ratio of absorbance at 260 and 280 nm was used to assess the purity of the nucleic acid. A 
ratio of ~1.8 was considered as pure DNA and a ratio of ~2.0 as pure RNA. 
Primers for standard PCR were designed using Primer3web tool (http://primer3.ut.ee/) 
(Utergrasser et al. 2012). Mutagenic primers for site-directed mutagenesis were designed 
using the PrimerX tool (http://www.bioinformatics.org/primerx/). 
 
4.12.3. Sequence alignment 
DNA and protein sequences were obtained from the NCBI database (www.ncbi.nlm.gov). 
Multiple sequence alignments were performed with T-coffee (Notredame et al., 2000). 
 
 
4.13. Protein expression and purification 
4.13.1. Protein Expression 
E. coli BL21 (DE3) cells transformed with pGEX-6P-1::Pur-alpha fragments were grown at 
37 °C in 3 litres of LB medium supplemented with 100 µg/ml ampicillin. 
For 15N-labeling of protein cells were grown in NMR medium. 
For selenomethionine-substituted protein the methionine auxotrophic E. coli strain B834 
(DE3) was used and cells were grown in SeMet medium. 
After reaching an OD600 of 0.6, cell cultures were cooled down to 18 °C and expression was 
induced at an OD600 of 0.8 by adding 0.25 mM IPTG. Cells were harvested after 12-16 hours 
of expression by centrifugation at 4 °C (4,000 rpm, 20 min). Pellets were resuspended in lysis 
buffer (500 mM NaCl, 50 mM Hepes, pH 7.5), flash frozen in liquid nitrogen and stored at -
80 °C.  
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4.13.2. Protein Purification 
All purification steps were carried out at 4 °C. After thawing, one tablet of EDTA 
(ethylenediaminetetraacetic acid)-free protease inhibitor cocktail (Roche, Germany) and 0.4 
mM PMSF (phenylmethylsulfonyl fluoride) were added to the cell suspension. Cells were 
lysed by sonication with a Branson Sonifier 250 (Emerson, Danbury, USA) (4x 4 min, 
amplitude 40 %, output 4) and cell debris was removed by centrifugation (16,000 rpm, 20 
min). GST-tagged proteins were purified by GST affinity chromatography (GE Healthcare). 
Therefore, the lysate was loaded onto a pre-equilibrated 5 ml GST-Trap FF column. After 
extensive washing with loading buffer, elution was done in 20 ml of elution buffer containing 
500 mM NaCl, 20 mM Hepes pH 8.0 and 25 mM glutathione. The GST tag was cleaved off 
by adding 50 µg PreScission–protease (GE Healthcare) prior to dialysis against buffer 
composed of 250 mM NaCl, 20 mM Hepes pH 8.0. After protease cleavage, the GST tag was 
removed using a GST column and nucleic acids were removed using a HiTrapQ column (GE 
Healthcare). Pur-alpha was further purified by a Heparin column (GE Healthcare) and 
subsequently eluted from the Heparin column with buffer containing 2 M NaCl and 20 mM 
Hepes pH 8.0. The elution fraction was concentrated in a centrifugal filter device (Amicon 
Ultra, Millipore, Billerica, USA), then centrifuged (13,000 rpm, 20 min) to remove aggregates 
and finally purified by size exclusion chromatography with a Superdex 75 10/30 GL column 
(GE Healthcare) in buffer composed of 250 mM NaCl or 500 mM NaCl (F I and F II mutant) 
and 20 mM Hepes pH 8.0. Peak fractions were again concentrated, centrifuged and either 
used for crystallization or flash frozen in liquid nitrogen with 10 % glycerol added and stored 
at -80 °C. For cysteine-containing and for selenomethionine-substituted proteins 2 mM DTT 
was added to all buffers. 
For NMR experiments size exclusion chromatography was performed in 50 mM potassium 
phosphate buffer pH 7.0 and 200 mM NaCl (NMR buffer). 
Absence of nucleic acid contamination was confirmed with UV-spectroscopy by measuring 
the ratio of absorbance at 260 nm and 280 nm. Only samples with a ratio A260/A280 of ≤ 0.6 
were used and considered as nucleic acid free.  
 
 
4.14. Methods for protein analysis 
4.14.1. SDS PAGE 
For monitoring purification progress and protein purity, as well as for western blot analysis, 
proteins were separated by dodecylsulfate polyacrylamide gel electrophoresis (SDS PAGE), 
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as described in Laemmli, 1970. Depending on the protein size, 10-15 % polyacrylamide gels 
were run, followed by Coomassie blue staining.  
 
4.14.2. Circular dichroism (CD) spectroscopy 
To confirm proper protein folding of the Pur-alpha derivatives CD spectra (wavelength 190-
260 nm) were recorded with a JASCO-715 spectropolarimeter at 5 °C in a 0.1-cm cuvette. 
Proteins were diluted in buffer containing 250 mM NaCl, 20 mM Hepes pH 8.0 and 2 mM 
DTT to a final protein concentration of 30 µM in 300 µl total volume. Five scans were taken 
with a speed of 50 nm/min. 
 
4.15. Structural biology 
4.15.1. Co-crystallization of Pur-α and nucleic acid and structure 
determination 
Crystals of selenomethionine-substituted Pur-alpha repeat I-II in complex with CGG 7mer 
ssDNA (ratio 1:2.2) were grown at 21 °C by hanging-drop vapor-diffusion using a 2:1 
mixture of protein-DNA-complex (final protein concentration 1.77 mg/ml) and crystallization 
solution containing 50 mM MES pH 5.2, 500 mM (NH4)2SO4, 1 mM TCEP and 16% PEG400. 
The drop size was 3 µl and the total reservoir volume 500 µl using the 24-well EasyXtal 
Crystal Support (Qiagen, Hilden, Germany). Rod-shaped crystals of 160x19.2 µm size 
appeared within 4 days. Prior to data collection crystals were cryoprotected in mother liquor 
and flash frozen in liquid nitrogen. Native dataset was recorded at beamline ID23-2 
[European Synchrotron Radiation Facility (ESRF) Grenoble, France]. Crystals diffracted up 
to 2.0 Å. Data were integrated and scaled with XDS (Kabsch 1993). Structure was solved by 
molecular replacement with PHASER (McCoy et al. 2007) using the apo-structure of 
Drosophila Pur-alpha 40-185 (PDB ID 3K44) and was completed using COOT (Emsley and 
Cowtan 2004). Refinement of the native data was performed with PHENIX (Adams et al. 
2010) using NCS and TLS. The final model was analyzed with SFCHECK (Vaguine et al. 
1999) PHENIX and REFMAC (Murshudov et al. 1997, Terwilliger 2002). Images of the 
crystal structure, superimpositions of the co-complex and apo-structure, as well as 
electrostatic surface potentials were prepared with PyMol (Schrodinger 2010) (DELano; 
http://www.pymol.org/). 
Crystallization trials of native and selenomethionine-substituted Pur-alpha repeat I-II (1.4-2.0 
mg/ml) in complex with RNA CGG 7mer (ratio 1:2.2) were performed in crystallization 
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solution containing 50 mM MES pH 5.0-5.8, 400-700 mM (NH4)2SO4, 1 mM TCEP and 8-
18 % PEG400, but yielded no crystals. 
 
 
4.16. Protein-DNA/RNA interaction studies 
4.16.1. RNase-free water 
All RNA experiments were performed with RNase-free materials, reagents and buffers made 
from RNase free water. RNase-free water was prepared by adding  (v/v) 0.05 % DEPC 
(diethylpyrocarbonate) (Roth, Karlsruhe, Germany) to Millipore-purified water. After 
incubation at 37 °C over night, the DEPC was inactivated by autoclaving. 
 
4.16.2. NMR experiments 
All NMR spectra were recorded in NMR buffer with 5 % D2O at 298 K using Bruker Avance 
III spectrometer equipped with TCI cryogenic probe heads, at field strengths corresponding to 
900 MHz proton Larmor frequency. To study DNA/RNA binding 1H 15N HSQC spectra were 
recorded of 15N-labeled protein (50 µM) titrated with nucleic acids with different 
stoichiometric ratio of protein:nucleic acid (1:0.25, 1:0.5, 1:0.75, 1:1, 1:1.25, 1:1.5, 1:2.5 and 
1:5). Spectra were acquired and processed with Topspin3.2 (Bruker, Karlsruhe, Germany) and 
analyzed with CCPNMR Analysis (Vranken et al., 2005). 
 
4.16.3. Isotopic labeling of oligonucleotides and primer 
For RNA-labeling RNase-free buffers, materials and reagents were used. 10 pmol of 
chemically synthesized DNA or RNA oligonucleotides were phosphorylated at the 5’-end 
with 10 pmol γ-32P ATP by T4 polynucleotide kinase (New England Biolabs, Frankfurt, 
Germany) with buffer A in a final volume of 20 µl. Labeling reaction was carried out at 37 °C 
and stopped after 30 min by incubation at 70 °C for 10 min. Labeled oligonucleotides were 
purified by a NucAway™ Spin column (Ambion, Austin, USA) and stored at -20 °C. 
For DNase I footprint experiments 10 pmol of MF0677 ssDNA (150nt) were labeled with 
17 pmol γ-32P ATP as described for oligonucleotides. The labeled DNA was then 
supplemented with 20 µl of formamide loading dye and purified by gel electrophoresis (400 V, 
90 min) using a pre-warmed 6 % TBE polyacrylamide gel with 8 M urea. The DNA band was 
visualized by radiograph films, cut out and extracted from the gel by crush & soak technique. 
Thereby, the DNA gel was cut into little pieces, which were incubated with 300 µl of 
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extraction solution (0.5 M ammonium acetate, 0.1 mM EDTA, (v/v) 0.1 % SDS) at room 
temperature over night. Next day the labeled DNA had diffused into the extraction solution, 
which was then transferred into a fresh Eppendorf tube. After addition of 900 µl of (v/v) 
100 % ethanol the labeled DNA was precipitated by incubation in a dry-ice/isopropanol bath 
for 30 min and subsequent centrifugation at 13,000 rpm for 30 min at 4 °C. After washing the 
DNA pellet with 1 ml of (v/v) 70 % ethanol and another centrifugation step (13,000 rpm, 10 
min), the pellet was dried in a Concentrator plus (Eppendorf, Hamburg, Germany) centrifuge 
for 10 min. The dried, labeled DNA pellet was finally resuspended in 20 µl Millipore-purified 
water and stored at -20 °C. 
 
4.16.4. Electrophoretic mobility shift assay (EMSA) 
The protein-nucleic acid complexes were formed in RNase-free binding buffer containing 250 
mM NaCl, 20 mM Hepes pH 8.0, 3 mM MgCl2, 4 % glycerol, 2 mM DTT). Serial protein 
dilutions and a constant amount of radiolabeled nucleic acid (2.5 nM) were incubated for 20 
min at 21 °C. DNA-binding experiments contained 25 µg/ml Salmon Sperm DNA, and RNA-
binding experiments contained 100 µg/ml yeast tRNA competitor. Samples were loaded onto 
6 % TBE polyacrylamide gels. After electrophoresis (45 min, 100 V) gels were incubated for 
15 min in fixing solution ((v/v) 10% acetic acid, (v/v) 30% methanol), dried in a gel dryer 
(BioRad, Munich, Germany) and analyzed with radiograph films in a Protec Optimax 
developer (Hohmann, Hannover, Germany).  
For fluorescence EMSA experiments 100 nM of fluorescein-conjugated nucleic acid was 
applied. Gels were analyzed directly after electrophoresis with a Typhoon 9200 scanner 
(Amersham Biosciences, Freiburg, Germany). Settings were as follows: 
 Emission filter: 526 SP Fluorescein/Alexa Fluor 488, PMT: 400-600, laser: Green (532), 
sensitivity: Normal, pixel size: 100 microns. 
 
4.16.5. SAXS (small angle X-ray scattering) 
All SAXS data were recorded on an in-house SAXS instrument (SAXSess mc2, Anton Paar, 
Graz, Austria) equipped with a Kratky camera, a sealed X-ray tube source and a two-
dimensional Princeton Instruments PI•SCX:4300 CCD detector (Roper Scientific, Sarasota, 
USA). Scattering curves were measured in a final volume of 50 µl with different buffers and 
different concentrations of protein only or protein-DNA complexes (see table below) in line 
collimation mode. Data were evaluated and processed with different programs from the 
ATSAS 2.1 software package (Konarev, Petoukhov et al. 2006). Primary analysis of the data 
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was done with PRIMUS (Konarev, Volkov et al. 2003) and data processing was performed 
using SAXSQuant software (version 3.9). Desmearing of the data, the forward scattering, I(0), 
the radius of gyration, Rg, the maximum dimension, Dmax, and the inter-atomic distance 
distribution functions, P(r), were computed with the program GNOM (version 4.6). 
 
Buffer Protein concentration Protein DNA  
Ratio 
protein:DNA 
50 mM potassium phosphate 
buffer pH 7.0, 200 mM NaCl 
50 µM Pur-alpha repeat I-II CGG DNA (7nt) 1:0, 1:1, 1:2 
20 mM Hepes pH 8.0, 350 mM 
NaCl 50 µM Pur-alpha repeat I-II 
MF0677 DNA (24nt) 
CGG DNA (7nt) 
1:0, 1:1, 1:2 
1:0, 1:1, 1:2 
20 mM Hepes pH 8.0, 500 mM 
NaCl, 2 mM DTT 50 µM Pur-alpha repeat I-III CGG DNA (7nt) 1:0, 1:1, 1:2 
20 mM Hepes pH 8.0, 1 M 
NaCl, 2 mM DTT 
50 µM Pur-alpha repeat I-III CGG DNA (7nt) 1:0, 1:1, 1:2 
Table 4. 21 SAXS conditions: buffers, protein concentrations and ratios 
 
4.16.6. Dot blot assay 
Dot blot assays were performed as described in Wong and Lohman, 1993. Protein was titrated 
to a constant amount of 1 µM MF0677 ssDNA (thereof 2.5 nM radiolabeled) in a final 
volume of 80 µl and incubated for 20 min at 21 °C in binding buffer 150 mM NaCl, 20 mM 
Hepes pH 8.0. Nitrocellulose filter (Roth, Karlsruhe, Germany) was presoaked for 10 min in 
0.4 M KOH followed by intensive washing with Milli-Q H2O. Nitrocellulose and nylon filters 
(Roth, Karlsruhe, Germany) were then equilibrated in binding buffer for 15 min. Both filters 
(nitrocellulose, top; nylon filter, bottom) were placed into a dot-blot apparatus (BioRad, 
Munich, Germany). Vacuum was applied and the wells were washed once with 80 µl binding 
buffer before and after samples were loaded. The nitrocellulose filters were analyzed using a 
phosphor imager system to measure the retained radiolabeled oligonucleotides on the 
nitrocellulose filter. Quantification was done using the dot blot analyzer plug-in of the ImageJ 
1.47v software (National Institute of Health, USA). 
 
4.16.7. Unwinding assay 
Unwinding assays were carried out according to Darbinian et al. 2001. A dsDNA substrate 
was prepared by annealing a complementary 18-mer oligonucleotide to a GGN motif of the 
M13mp18 ssDNA plasmid. The 18-mer (GGN) was labeled with γ-32P ATP. Protein dilutions 
were added to a constant amount of dsDNA substrate (100 ng) in binding buffer composed of 
150 mM NaCl, 20 mM Hepes pH 8.0. Samples were incubated at 37 °C for 1 h. The 
unwinding reaction was stopped by adding SDS to a final concentration of (v/v) 0.3 %. 
Samples were run on 9 % native polyacrylamide gels in 1x TBE buffer for 2 h 30 min at 
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200 V. Gels were incubated for 15 min in fixing solution ((v/v) 10 % acetic acid, (v/v) 30 % 
methanol), dried in a gel dryer and analyzed with radiograph films. 
 
4.16.8. DNase I footprint 
Radioactivity of labeled oligonucleotides was measured with the liquid scintillation analyzer 
TriCarb 2100TR (PerkinElmer, Massachusetts, USA) using the Cerenkov protocol 
(3H channel). In a final volume of 25 µl, 100.000 counts per minute (cpm) of 5’end-
radiolabeled ssDNA (150 nt) or dsDNA (160 nt), gained from restriction digest of pEX-A-
MF0677 with HindIII and SacI, containing the myc-MF0677 sequence were applied for 
incubation with different protein concentrations for 20 min on ice. After addition of MgCl2 
and CaCl2 to a final concentration of 7 mM and 3 mM, respectively, the protein-DNA-
complex was digested at RT with DNase I (1-50 unit/ml). Cleavage was stopped after 1 min 
by adding an equal volume of DNase I stop solution (20 mM EDTA; 1 % SDS; 0.2 M NaCl, 
100 µg/ml yeast tRNA). Subsequently, DNA fragments were extracted with 
phenol:chloroform followed by ethanol precipitation according to Sambrook and Russell, 
2001. Dried DNA pellets were dissolved in formamide loading dye and boiled at 100 °C 
before loading on the gel. 
For the sequencing reaction 100.000 cpm of radioactively labeled primer were annealed to 
250 fmoles of unlabeled myc-MF0677 ssDNA (150 nt) in 5x reaction buffer (200 mM Tris-Cl 
pH 8,8 and 25 mM MgCl2) for 2 min at 65°C and afterwards cooled to RT. Then 4 µl of each 
ddNTP Chain Extension/Termination mixture (15 µM of dNTP; ddNTP:dNTP ratios 30:1; 
80:1, 80:1 and 30:1 for cytosine, thymine, adenine and guanine, respectively) was added 
together with 8 µl of Taq DNA-polymerase (1 unit/µl; diluted in 25 mM Tris pH 8,8; 
0,01 mM EDTA pH 8,0; 0,15 % Tween-20 and 0,15 % Nonidet P-40). Probes were incubated 
at 72°C for 10 min. Sequencing reaction was stopped by adding formamide loading dye and 
boiling at 100°C. 
The DNase I cleavage probes and the sequencing reactions were loaded with an equal amount 
of cpm onto 6 % TBE polyacrylamide gels with 8 M urea. After electrophoresis (90 min, 
1800 V) gels were incubated for 15 min in fixing solution ((v/v) 10 % acetic acid, (v/v) 30 % 
methanol) and analyzed with radiograph films.  
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4.17. Cell culture 
4.17.1. Cell cultivation 
All reagents and materials used for cell culture were sterile. HeLa and COS7 cells were 
maintained in 75 cm2 flasks (Greiner Bio-One, Frickenhausen, Germany) with Complete 
medium at 37°C in a humidified incubator of 5% CO2. For splitting and seeding Complete 
medium was removed from the flasks and cells were washed with 10 ml 1x PBS. Trypsin-
EDTA was diluted in 1x PBS to a final concentration of (v/v) 0.05 %. To detach the adherent 
cells from the flask 2 ml of diluted Trypsin-EDTA was added and flasks were incubated at 
37 °C for 5 min. Trypsination was stopped with 10 ml Complete medium. Subsequently, the 
cell suspension was transferred to Falkon tubes (BD Biosciences, Heidelberg, Germany) and 
centrifuged at 1,200 rpm for 5 min. After discarding the supernatant, the cell pellet was 
resuspended in fresh Complete medium and the required amount of cells were transferred to 
new flasks (splitting) or 6-well plates (seeding). For seeding cells were counted with a 
Neubauer counting chamber and the required cell number depending on the experiment was 
transferred into 6-well plates. 
 
4.17.2. Transfection 
The previous day to transfection 0.5-2x105 cells were seeded into 6-well plates. When cells 
were 70-90 % confluent they were transfected using the Lipofectamine 2000 (Invitrogen, 
Karlsruhe, Germany) or the FuGENE HD (Promega, Mannheim, Germany) transfection 
reagent according to the manufacturer’s protocol. 
The amount of transfected DNA depended on the experiment: 
Transfection of BAC (bacterial artificial chromosome) constructs: 100-250 µg DNA/well. 
Transfection of CGG-repeat RNA constructs (pRTR, pRTS-1): 10 µg DNA/well. 
 
4.17.3. Induction of protein/RNA expression 
24 hours after transfection of the pRTR or pRTS-1 constructs, expression was induced by 
adding doxycycline to a final concentration of 1 µg/ml to the medium. Successful transfection 
and induction was verified by western blot or by monitoring the eGFP signal with a Biorevo 
BZ-9000 (Keyence, Neu-Isenburg, Germany) fluorescence microscope at 10x lens 
magnification and analysis with the BZ-II Analyzer software. 
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4.17.4. Establishment of a stable cell line expressing tagged human Pur-α 
A BAC clone containing the genomic sequence of human Pur-alpha plus flanking regulatory 
regions was ordered from Empire Genomics (RP11-1106D15 in pBAC 3.6). For N- and C-
terminal tagging of Pur-alpha two eGFP tagging cassettes (N-terminal tagging: R6K-NFLAP; 
C-terminal tagging: R6K-LAP) were kindly provided by Ina Poser (MPI Dresden). BAC and 
oligo sequences for BAC tagging were taken from the homepage of BACFinder-MitoCheck 
(www.mitocheck.org/cgi-bin/BACfinder). Tagging was performed using the Quick and Easy 
BAC Modification Kit (Gene Bridges) according to the manufacturer’s protocol and Poser et 
al. 2008. Successful tagging was verified by amplification of eGFP via PCR. 
The BAC constructs containing either N- or C-terminally eGFP tagged human Pur-alpha were 
then transfected into HeLa cells. Different amounts (6, 9, 12 or 15 µl) of Lipofectamine 2000 
were used according to the manufacturer’s protocol. Two days after transfection, cells were 
cultivated in media supplemented with 50 µg/ml G418 for selection. After additional 3 days 
the concentration of G418 was increased to 400 µg/ml and media was changed every 2-3 days 
to remove dead cells and cell debris. Within the next 3-4 weeks untransfected cells were dead. 
After 5 weeks G418 resistant colonies were further amplified into 75 cm2 flasks. Cells were 
maintained in media containing 500 µg/ml G418. Expression of eGFP-tagged protein was 
analyzed with fluorescence microscopy and Western Blot. Cloning plasmids and 
oligonucleotides employed can be found in chapter 4.4. 
 
4.17.5. Establishment of a stable cell line expressing CGG-repeat RNA 
The two vectors, each containing the 5’UTR of the fmr1 gene followed by either 30 or 95 
CGG repeats (pCEP4-TRE-(CGG)n-eGFP) were a kind gift of Prof. Flora Tassone 
(University of California, USA). The inserts were cut out with BlpI/XhoI, sticky ends were 
filled up in a PCR (Sambrook and Russell 2001) with Vent®-polymerase (Hukema et al.) in 
order to ligate the construct into the cloning vector pUC19-SfiI (obtained from Prof. Georg 
Bornkamm, Helmholtz Zentrum München) linearized by enzymatic digestion with EcoRV. 
To tag the CGG repeat RNA, 27 PP7 stem loops from the pCR4-24xPP7-SL vector (created 
by Prof Ralf Jansen, MPI Tübingen) were cut out via BamHI and ligated upstream of the fmr1 
5’UTR at the BamHI restriction site. The new insert, containing 27 PP7 stem loops fused to 
the fmr1 5’UTR followed by CGG repeats, was then cloned into the final mammalian 
expression vector pRTS-1 via “cut and paste” with SfiI restriction enzyme. Prior to that, the 
PP7 coat protein, which recognizes and binds to PP7 stem loop structures, was amplified by 
standard PCR (primer 15 and 16) from the pET22HT-PP7delFG plasmid (provided by Prof. 
Ralf Jansen, MPI Tübingen) and cloned into the pRTS-1 vector in frame at the N-term of the 
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eGFP gene at the SwaI restriction site. All cloning steps were verified either by sequencing or 
restriction digest.  
The PP7 stem loop-fmr1 5’UTR-(30 or 95 CGG) insert and the PP7 coat protein fused to 
eGFP was also cloned into the pRTR vector, which additionally encodes for the CD2 gene 
and enables cell selection via Dynabeads® (Invitrogen, Karlsruhe, Germany). 
Constructs were then transfected into HeLa or COS7 cells and protein/RNA expression was 
induced with doxycycline. Expression of eGFP-tagged PP7 protein was monitored by 
fluorescence microscopy. 
 
 
4.18. Western Blot 
4.18.1. Cell harvest and lysis 
HeLa and COS7 cells were harvested from 6-well plates. The medium was removed and cells 
were washed once with 2 ml per well of 1x PBS. Depending on the density of the cells 75 µl 
(less dense) or 100 µl (dense) of 2x magic mix was added to each well. Cells were scraped off 
with a cell scraper (TPP, Trasdingen, Switzerland), transferred to a QIAshredder filter column 
(Qiagen, Hilden, Germany) and centrifuged at 13,000 rpm for 2 min. The flow through was 
flash frozen in liquid nitrogen and stored at -80 ˚C. 
 
4.18.2. Determination of total protein concentration 
Total Protein concentration was measured by using the Quant-iT™ Protein Assay Kit 
(Invitrogen, Karlsruhe, Germany) with the Qubit™ Fluorometer (Invitrogen, Karlsruhe, 
Germany) according to the manufacturer’s protocol.  
 
4.18.3. Blotting and immuno-staining of proteins 
20 µg of total protein per lane was loaded onto a 10 % polyacrylamide gel (SDS PAGE) and 
separated for 1 h 15 min at 150 V. Subsequently the gel was equilibrated for 15 min in 1x 
Semi-dry transfer buffer. The nitrocellulose blotting membrane was equilibrated for 3 s in 
methanol, 2 min in bidestilled H2O and 15 min in 1x Semi-dry transfer buffer. Proteins were 
then blotted onto the membrane in a Semi-dry-blotter (Peqlab (VWR), Erlangen, Germany) at 
200 mA for 45 min. To saturate unspecific proteins, the blot was incubated in (w/v) 5 % milk 
powder/PBST over night at 4˚C. The next day, the blot was incubated with the primary 
antibody diluted in (w/v) 1 % BSA/PBST for 1h at RT or over night at 4˚C. Three washing 
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steps (5 min each) with PBST followed to remove unbound antibody. The corresponding 
HRP conjugated secondary antibody was diluted in PBST and was incubated with the blot for 
45 min at room temperature, again followed by three washing steps with PBST. Protein 
signals were detected by incubating the blot with the Pierce ECL substrate (Thermo Fisher 
Scientific, Bonn, Germany) for 1 min and subsequent exposure to light-sensitive films (GE 
Healthcare, Munich, Germany).  
 
4.18.4. Antibody testing (αB-crystallin, Pur-α) 
15 in house produced tissue culture supernatants of the αB-crystallin antibody (raised against 
the C-terminal peptide R-E-E-K-P-A-V-T-A-A-P-K-K-Y-COOH (Bhat et al. 1991), three 
tissue culture supernatants of the human Pur-alpha antibody (Jurk et al. 1996) and a 
commercial human Pur-alpha antibody have been tested in western blot assays. Therefore 
2x105 COS7 or HeLa cells per well were seeded into 6-well plates. Next day cells were 
harvested and 20 µg of total protein per lane were separated on a 10 % SDS gel and blotted 
onto a nitrocellulose membrane. Each blot was first incubated with the primary antibody for 1 
h at room temperature followed by incubation with the corresponding HRP conjugated 
secondary antibody for 45 min at room temperature. Protein signals were detected using the 
ECL substrate and blot exposition to light-sensitive films. 
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5. Appendix 
5.1. Abbreviations 
 
% Per cent m Milli, meter 
°C Degree Celsius M mol per Liter, 
methionine 
µ Micro MES 
2-(N-
morpholino)ethanesulfo
nic acid 
A  Alanine (amino acid) or 
adenine (nucleic acid) 
min Minute 
Å Ångström n Nano 
A280, A260, A254 
Absorption at 83avelength 
260 nm/ 280 nm / 254 nm 
nt Nucleotide 
aa Amino acid nm Nanometer 
Amp  Ampicillin NaCl Sodium chloride 
ATP  Adenosine triphosphate n.d. Not determined 
bb,  B. burgdorferi Borrelia 
burgdorferi 
OD600 Optical density at 600 
nm 
BAC 
Bacterial artificial 
chromosome N-term Amino-terminus 
BSA Bovine serum albumin P Proline 
C  Cysteine, cytosine PAGE Polyacrylamide gel 
electrophoresis 
CD  Circular dichroism PCR 
Polymerase chain 
reaction 
Ci  Curie PEG Polyethlyleneglycol 
CNS Central nervous system pH Potentia hydrogenii 
C-term Carboxy-terminus PMSF 
Phenylmethanesulphon
ylfluoride 
D Aspartic acid PVFD Polyvinylidene fluoride 
Da  Dalton  R Arginine 
deg  Degree rev Reverse 
DEPC Diethylpyrocarbonate RMSD Root-mean-square 
deviation 
dm, D. melanogaster  Drosophila melanogaster (m)RNA 
(messenger) 
Ribonucleic acid 
DNA  Desoxyribonucleic acid RNP 
Ribonucleoprotein 
particle 
ds  Double stranded rpm Rounds per minute 
E  Glutamic acid RT Room temperature 
E. coli  Escherichia coli s Second 
EDTA  Ethylenediamine-
tetraacetic acid 
S Serine 
EMSA  
Electrophoretic mobility 
shift assay SAXS 
Small angle X-ray 
scattering 
F  Phenylalanine SDS Sodium docecyl sulfate 
for  Forward SeMet Selenomethionine 
g  
Gram or standard 
accelaration ss Single stranded 
G  Guanine TCEP 
Tris-(2-carboxyethyl)-
phosphine hydrochlorid 
GST Glutatione S-transferase TRIS tris(hydroxymethyl)ami
nomethane 
h  Hour or human tRNA Transfer RNA 
HEPES 
(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
UTR Untranslated region 
I Isoleucine UV Ultraviolet 
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IPTG Isopropyl-β-D-
thiogalactopyranosid 
v/v Volume per volume 
K Lysine, Kelvin WT Wild type 
k Kilo w/v Weight per volume 
Kan Kanamycin Y Tyrosine 
KD 
Equilibrium dissociation 
constant   
l Liter   
L Leucine   
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